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Abstract 
The primary purpose of understanding disease etiology is to explain how a specific 
phenotype is determined by genotype. In pursue of this aim, exploring the diversity 
in DNA sequence variants that affect biomedical traits, especially those related to 
the onset and progression of genetically determined human disease. The human 
leukocyte antigens (HLA) are highly polymorphic cell surface proteins encoded in 
the major histocompatibility complex (MHC) region on chromosome 6. The HLA 
molecules are integral regulators for susceptibility to several autoimmune and 
inflammatory diseases, including type 1 diabetes (T1D) and celiac disease (CD), 
which share high-risk HLA haplotypes. Through next-generation sequencing 
(NGS), an integrated genotyping system of HLA loci was developed to genotype 
alleles of the MHC region. The full depth of allele association was used to target the 
novel mechanisms of HLA-associated risk alleles in T1D and CD.    
The research presented in this thesis aimed to use high-resolution genotyping with 
NGS of HLA loci and study extended associations in patients with T1D and CD as 
well as in a group of patients affected by both diseases (T1D w/CD).  
The main findings of importance were: - 
• HLA-DRB3, DRB4, and DRB5 affect the risk of islet autoimmunity and 
progression to the clinical onset of T1D and should be considered when 
examining the role of HLA-DR genetic risk.  
• Two distinct CD risk DR3-DQA1*05:01-DQB*02:01 haplotypes 
distinguished by either HLA-DRB3*01:01:02 and DRB3*02:02:01 alleles 
in the DRB3*01:01:02- DQA1*05:01-DQB1*02:01 extended haplotype 
distinguished the risk of CD, indicating that different DRB1*03:01-
DQB1*02:01 haplotypes confer different risks for CD among patients of 
Scandinavian background.  
• HLA-DRB4*01:03:01, DRB3*01:01:02, and DRB3*02:02:01 are 
associated with T1D and CD of which DRB4*01:03:01 confers the 
strongest risk allele for T1D w/CD. 
• HLA-A*68:01:02 was identified as an additional allele positively associated 
between T1D w/CD and T1D.  
In conclusion, by utilizing high-resolution sequencing technologies for extended 
genotyping of HLA class I and II genetic determinants, the full spectrum of alleles 
and haplotypes variation associated with T1D and CD were explored. This basic 
knowledge should prove helpful contribution in building comprehensive inventories 
of genotype-phenotype relationships and resolving some of the HLA roles in the 
heritability risk for either T1D or CD, as well as in genetic models for the risk of 
developing both diseases.   
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Introduction 
Type 1 diabetes (T1D), known also as autoimmune diabetes, is a chronic endocrine 
disease characterized by a pancreatic β-cells loss that leads to insulin deficiency 
resulting in hyperglycemia complications (1-3). Celiac disease (CD) is a chronic 
immune-mediated enteropathy induced by ingested dietary gluten, which is present 
in grains, including wheat, rye, and barley (4, 5). The susceptibility to T1D and CD, 
in which the immune system plays a significant role, has a strong genetic 
background, as demonstrated by diseases concordance in monozygotic twin pairs  
(6, 7). The rate of familial disease clustering in T1D patients is 6% in siblings 
compared to 0.4% clustering rate in the general population, and 50% concordance 
rate in monozygotic twins (6, 8). The average pooled prevalence of CD among first-
degree relatives (FDR) exceeds that of the general population by 7.5%–15% (9, 10) 
and concordance around 80% in monozygotic twins and less than 20% among 
dizygotic twins (7, 11). Genetics is the cornerstone of disease etiology in CD (12) 
and T1D(13), of which specific human leukocyte antigen (HLA) genes are located 
in the major histocompatibility complex (MHC) on the short arm of chromosome 6 
(6p21.3) confer the strongest risk association. This introduction summarizes the 
current state of knowledge of HLA susceptibility in T1D and CD. 
History of HLA-associated diseases 
The discovery of the association between the HLA-B gene and Hodgkin lymphoma 
was the first link between HLA genes and human disease (14). The association 
between HLA risk genes and autoimmune diseases was first described more than 50 
years ago (15). HLA-B*27 (called HL-Aw27 previously) link with ankylosing 
spondylitis was the first reported discovery between HLA risk and autoimmune 
diseases (16). The association of HLA with T1D was first reported in the 1970s (17, 
18). Meanwhile, the association between the HLA region and CD development was 
also discovered (19-21). 
Similarly, HLA association was also observed for several other autoimmune and 
inflammatory diseases, including systemic lupus erythematosus (SLE), rheumatoid 
arthritis (RA), and multiple sclerosis (MS) as well infectious disease (for example, 
DRB1*1302 is protective against chronic hepatitis B virus (22)) and even 
neuropsychiatric disorders underscoring the central importance of HLA risk to 
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physiology, protective immunity and deleterious, disease-causing autoimmune 
reactivity (7). To date, genes in the HLA region are still the primary genetic risk 
determinants for T1D and CD, accounting for the major share of the genetic 
susceptibility to diseases, estimated from studies of affected sibling pairs (23). 
However, even with a large body of defined genetic associations between HLA and 
many autoimmune diseases have been identified, most genetic risk associations in 
the HLA complex remains unexplored. 
MHC region gene structures  
The HLA region encoding for the MHC antigen-presenting receptor molecules is 
generally organized into three subclasses (Fig.1, left):  
• HLA class I region, including the classical, highly polymorphic HLA-A, 
HLA-B, and HLA-C heavy chain paralogues, besides the non-classical HLA-
E, HLA-F, and HLA-G genes.  
• HLA class II region, including HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-
DQA2, HLA-DQB1, HLA-DQB2, HLA-DRA, HLA-DRB1, HLA-DRB2, 
HLA-DRB3, HLA-DRB4, and HLA-DRB5 as well as fewer variable genes.   
• Finally, the HLA class III region, which contains genes implicated in 
inflammatory responses, leukocyte maturation, and the complement 
cascade.  
Classical MHC molecules are cell-surface membrane glycoproteins that 
function in serological specificity by binding and presenting protein-peptide 
antigens recognized by the T cell receptor (TCR). MHC molecules are 
generally categorized into two principal classes, with three main kinds of 
antigens in each class. MHC class I molecules A, B, and C comprise a 
protein polypeptide chain that forms a heterodimer shape consisting of a 
heavy chain adjunct with a relatively invariant β-2 microglobulin protein. 
Class I molecules act a principal function by presenting peptides processed 
by the endoplasmic reticulum to the immune cells. They are expressed in 
nearly all nucleated cells. The HLA-DR, -DQ and -DP genes encode MHC 
class II molecules and consist of a heterodimer consisted of two 
polypeptides: an α and a β chain (alpha and beta), both anchored in the cell 
membrane of antigen-presenting cells (B lymphocytes, dendritic cells, 
macrophages). The overall structure of MHC molecules is relatively 
similar, as that is illustrated schematically in (Fig.1, right). 
15 
 
Figure 1. A simplified location organization of the HLA complex on chromosome 6 ( left figure). A schematic structure 
of MHC class I and class II molecules (right fgure). (Adapted from Klein, J., & Sato, A. (2000). The HLA system. N 
Engl J Med, 343(10), 702–709) 
16 
The initial structural explanation of the HLA-A2  protein structure in 1987 showed 
that the extracellular portion of the protein transform by folding into a β-pleated 
sheet on which two α-helices create a groove or a channel into which peptides 
bind (24, 25). The shape and charges within the peptide-binding groove dictate the 
peptides' repertoire that can bind to a specific HLA antigen. The TCR identify the 
combination of HLA protein and antigen peptide, creating what is known as the "tri-
molecular complex" that initiates the immune response, as shown in (Fig. 2). 
 
Figure 2. Molecular basis of TCR–MHC recognition. 
The classical TCRαβ complex formed of cell surface receptors CD3ζ, CD3γ, CD3δ and CD3ε chains. The MHC class I 
molecule consists of an α chain and a β2-microglobulin chain. The MHC class II molecule is composed of two non-
covalently associated α and β chains. (Adapted fromJoglekar, A.V., Li, G. T cell antigen discovery. Nat Methods 
(2020)).  
HLA gene mappings  
The HLA genomic loci map is located on chromosome 6 (6p21) short arm (26) (Fig. 
3). The order of the exons and introns in HLA-encoding genes is analogous, in 
which the signal peptide of the surface receptor is encoded in exon 1 containing 5′ 
untranslated sequence (UTR), and immunoglobulin-like domain of MHC 
extracellular portion of the MHC molecule is encoded by exons 2 and 3 (exon 4 for 
class I genes). 
17 
 
Fig.3 The HLA region location on the short arm of chromosome 6.  
The HLA class II genes at the DRB3, DRB4, and DRB5 along with DRB1* as well as DQA1*-B1* are tightly organized 
and LD strongly affecting risk associations in HLA-linked diseases.( Adapted from Autoimmune (type 1) diabetes. / 
Lindbladh, Ida; Svärd, Agnes Andersson; Lernmark, Åke.The Autoimmune Diseases. ed. / Noel R. Rose; Ian R. 
Mackay. 6. ed. Academic Press, 2019. p. 769-787) . 
Exons 2 and 3 in HLA class I genes (e.g., HLA-B) and exon 2 from each of the HLA 
class II two genes encoding an HLA class II antigen molecule (e.g., HLA-DQA1 
and DQB1), define the cell surface receptor peptide-binding groove and considered 
the essential determinants of antigen specificity. HLA genes exons encoding the 
peptide-binding groove are the most polymorphic sites in the HLA region. The 
reason for the polymorphism in these exons is speculated to result from natural 
selection. Old conventional HLA genotyping methods minimally extends the 
genotyping of those core exons in comparison to new methods. A single HLA class 
I gene (HLA-A, B, and C, respectively) encode for each HLA class I (A, B, and C) 
protein. Two different genes are responsible for creating the heterodimer molecule 
of HLA class II antigens. Accordingly, the translation of two different genes, e.g., 
in the DQ antigen, HLA-DQA1 encodes the α chain, and HLA-DQB1 encodes the β 
chain; in the DP antigen, HLA-DPA1 encodes the α chain, and HLA-DPB1 encodes 
the β chain, and in the DR antigen, HLA-DRA1 encodes the α chain, and HLA-DRB1 
encodes the β chain. DRβ chains can be encoded by additional HLA loci found on 
different chromosomes. HLA-DRB1 is located on all copies of chromosome 6. 
Some DRB genes are regarded as pseudogenes, but not for HLA-DRB3, DRB4, and 
DRB5 as they all produce a functional DRβ chain that can dimerize with the 
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translated protein of the DRA1 gene. The HLA-DRB3, DRB4, and DRB5 genes are 
commonly designated as a single DRB345 allele because they segregate as a single 
unit locus, but they are separate loci and not different alleles of the same locus. 
Because of the pattern in which HLA haplotypes evolved, a given class II haplotype 
can only have zero or one of these secondary, expressed DRB alleles, which is highly 
dependent on the identity of the DRB1 allele on that haplotype. Thus, the data for 
these loci are often assigned to three different alleles of a single locus as DRB345.      
The MHC locus exhibits two unique features: extreme polymorphism and strong 
linkage disequilibrium within a range possibility. These peculiar characteristics 
have made the localization of the specific genes and alleles responsible for disease 
association signals in the region difficult. Genes on a given chromosome are said to 
be linked if alleles at respective genes show a non-random pattern of association 
between alleles at different loci within a population; those alleles are considered to 
be in linkage disequilibrium (LD) (27). Genetic analysis of HLA loci mapped the 
HLA-C and B genes to be situated within a 90-kb region at chromosome 6p21.33 
(28). Allele combinations of these specific two genes are often preserved because 
of LD, likely be derived from a shared ancestral chromosome segment. The LD 
between HLA-B and C is initially called the HLA-B~C haplotype block (29). As in 
the  HLA-B~C block, HLA class II genes HLA-DRB3, DRB4, and DRB5, DRB1, 
DQA1, and DQB1 genes within the HLA class II region are located in a 150 - 210-
kb range at chromosome 6p21.32 (28). Consequently, alleles of these genes are also 
in strong LD and constitute what has denominated as the HLA-DR~DQ block (30). 
HLA gene polymorphism and nomenclature 
HLA genes are the most polymorphic genome identified in the human genome(26, 
31) and are associated with the highest number of human diseases in the 
genome(32). In comparison to most human genes that have only one form or have 
a few variant sequences, the classical HLA genes can have thousands of variable 
alleles, as seen in their extreme polymorphism (Table 1). There are currently more 
than 27,980 HLA alleles described by the HLA nomenclature and listed in the 
IPD-IMGT/HLA published database (Release 3.41.0, 2020-07-13) (33, 34). As 
the updated database shows, most polymorphism for MHC class I is seen in 
the HLA-B, in contrast to the HLA-A and HLA-C genes. This variable pattern of 
polymorphism also manifested in MHC class II DR encoding genes, where the 
DRB1 gene is hugely polymorphic, while the DRA1 gene is considerably invariant. 
The heterogeneity of the DR antigens on the cell surface is increased in haplotypes 
by pairing a second DRB with the DRA1 gene. The polymorphism in HLA class II 
DQ genes encoding the two antigen polypeptides results in differentiating the 
possible types of cell-surface DQ receptor molecules to four by combinational 
heterogeneity. For DP gene, almost all of the variability is encoded in the DPB1 
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gene compared to DPA1 gene limited polymorphism, and generally, only a small 
number of DPA1 alleles are seen in each population. 
Table 1.  Classical HLA loci extreme polymorphism. 
Number of identified alleles for each classical HLA gene as it published on IPD-IMGT/HLA database(2020 release). 
HLA Locus Number of identified alleles 
HLA class I loci              A 
                                      B 
                                      C 
6,192 
7,431 
6,067 
 
HLA class II loci           DRA 
                                     DRB1 
                                     DRB3  
                                     DRB4 
                                     DRB5 
                                     DQA1 
                                     DQB1 
                                     DPA1 
                                     DPB1 
29 
2,737 
345 
166 
130 
260 
1,857 
202 
1,584 
 
Frequent updating in HLA nomenclature used was required because of the rapid 
surge in the number of identified HLA alleles. The current nomenclature was first 
designated in April 2010 with frequent updates, as illustrated in Fig. 4. The 
nomenclature system uses numeric fields divided by colons to represent four levels 
of resolution (33). Briefly, the 1st field (formerly 2-digit level) is the serological 
definition of related allele groups. The 2nd field (4-digit) differ in their unique HLA 
protein sequence. Finally, the 3rd and 4th fields describe alleles harbouring 
synonymous silent polymorphisms, including exonic coding and non-coding 
variations. 
 
Figure 4. Human leukocyte Antigen (HLA) nomenclature 
(From Nunes, E., Heslop, H., Fernandez-Vina, M., et al. (2011). Definitions of histocompatibility typing terms. Blood, 
118, e180–e183) 
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Early DPB1 alleles nomenclature numbered the alleles in order of their discovery, 
regardless of serologic reactivity, because few serologic reagents were developed 
before the availability of DNA-based genotyping. With more genotyping of more 
DPB1 alleles,  the nomenclature system was required to add the colon field 
separators in the later update (35). 
Data interpretation can be challenging to interpret among studies performed with 
different genotyping methods due to many identified alleles. This reason impedes 
the ability to produce allele-level genotype recognition with all the highest-
resolution sequencing. For instance, high-resolution genotyping can distinguish 
specific allele designations on the fourth field, including sequencing of intronic and 
untranslated sequences. Fortunately, the relevant evidence for function resides is 
shown in the first two serology fields (four-digits), which define the amino acid 
sequence of the encoded HLA protein for most disease genetic association studies. 
Generally, the silent polymorphisms and polymorphisms in intronic and 
untranslated regions do not affect the function, and the first two-field resolution is 
sufficient.  
HLA genotyping progression  
HLA genotyping technology is developing at an accelerated pace. Measurement of 
sensitization to tissue histocompatibility differences began early in the 1960s. It was 
first noticed when patients receiving several transfusions of ABO compatible blood 
experienced an unexpected immune reaction where antibodies were being produced 
against donors’ white blood cells and that these antibodies triggered another 
immune reaction in half the samples of other white blood cells donors. Initially 
called the factor responsible for the immune reaction the MAC, then was recognized 
as the first of a group of human leukocyte antigens, or HLAs. The first 
histocompatibility testing was conducted by applying cell-based techniques using 
multiparous women serum for fetus blood group testing. Extensive standardization 
among the different HLA typing laboratories of testing reagents and sequencing 
protocols was justified, and HLA genotyping assays evolution resulted in low-
resolution sequencing with many spaces. The use of DNA-based genotyping 
technology during the 1980s enhanced the sequence reading and the determination 
of the individual HLA alleles present in study subjects which resulted in an 
increased number of discovered alleles that led to the first complete sequence-based 
gene map that analysed  224 gene loci and studied 128 (57%) loci expression in 
1999(36) and continuously going on. Initial DNA technology applied restriction 
fragment length polymorphism (RFLP) using restriction enzymes and Southern 
blotting (37). Polymerase Chain Reaction (PCR) techniques allowed the 
development of numerous PCR-based genotyping methods, including the use of 
sequence-specific oligonucleotide probe hybridization (SSOP) in analysing 
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amplified β-globin and HLA-DQ (38), typing of HLA-DR by sequence-specific 
priming (SSP) (39), and sequence-based typing (SBT)of HLA-class II (40).  
The DNA sequencing technology that has revolutionized the genomics research 
currently is the next-generation sequencing (NGS)-based method on the Illumina 
platform, in which DNA is fragmented and quickly sequenced to produce short 
sequencing reads with low-cost. A platform that leverages a sequence-by-synthesis 
approach to arrange the order of nucleotides in a DNA strand(41). Illumina’s DNA 
sequencing technology constructs highly accurate (higher than 99.9%) sequencing 
reads, which are reasonable to produce on a massive scale. These advantages have 
prompted the ascent of the Illumina platform to become the current gold standard 
of clinical and research sequencing that led to innumerable scientific discoveries 
over the past decade that have enhanced our understanding of evolution, adaptation 
and disease pathogenesis through the discovery of pathogenic variants (42). The 
specificities of each of the most common sequencing platforms selected according 
to their strengths and weaknesses for HLA sequencing for a given study, depends 
on their intended use. For instance, a simple clinical test can be more cost-effective 
than the full sequencing of HLA-B*27 to diagnose ankylosing spondylitis disease. 
However, typing and eventually matching donors and recipients in solid organ and 
hematopoietic stem cell transplantations (HSCT) are particularly genotype-specific, 
underlining the importance of DNA genotyping for at least two-field resolution of 
HLA genes for organ-rejections operations decisions in case of organs 
transplantation surgeries.  Table 2 illustrates the resolution levels of various HLA 
genotyping methods. 
Table 2.  
Resolution levels of HLA genotyping methods shown in increasing level of genotyping resolution (35).  
Resolution Level Genotyping Method Sequencing Fields 
Low SNP imputation Varies 
Low Serology 1 
Low SSP Up to 3 
Low SSO 3 
Low SBT 3 
High NGS (exon-based) 3 
High NGS (with introns and UTR) 4 
 
Next-generation sequencing (NGS) is currently applied for HLA genotyping (43-
45). HLA genotyping using (NGS) is becoming a successful approach in research 
and clinical laboratories. Recent advances in immunogenetics genotyping unlock 
the gateway to implementing HLA typing in risk stratification of diseases in the 
clinic (46) in comparison to the costly slow conventional methods such as Sanger 
sequencing or Sequence‐Specific Oligonucleotides probe hybridization 
(SSOP)/Sequence‐Specific Priming (SSP) (47, 48). Besides that, NGS has allowed 
quintessential insights in “single‐molecule sequencing” of the growing number of 
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polymorphic HLA alleles by typing all exons and introns through combining clonal 
(single‐molecule) sequencing and a high level of parallelism for a potential full 
understanding of regulation and expression of these genes(49). All DNA sequencing 
innovations have raised the level of resolution of the genotyped data as shown in 
generational progression (Fig. 6). 
  
Figure 6. Different DNA sequencing technologies evolution.  
Schematic illustrations of first, second and third generation DNA sequencing. Second generation sequencing is also 
referred  as next-generation sequencing (NGS) (adapted from J Shendure et al. Nature 1–9 (2017)) 
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NGS systems generate substantial numbers of “clonal” sequence reads derived from 
subject DNA molecules, in a massively parallel fashion. The key advantages of NGS 
clonal kind enable each sequence read assigned to a single allele, resulting in an in-
depth analysis of HLA types by phasing linked polymorphisms and resolve cis-trans 
ambiguities more than those obtained from more popularly used Sanger-sequencing 
based typing (SBT) methods (50, 51). NGS platforms can return full-length (four-
field) alleles and detect novel alleles by generating at once many more sequences 
reads than SBT instruments, yielding non-core exons, introns, and untranslated 
regions to be sequenced in addition to core exons (52). By applying next-generation 
sequencing (NGS), an integrated genotyping system of HLA genes exons 1–4 was 
developed to extend genotyping of all DRB1, DRB3, DRB4, and DRB5 alleles (53, 
54).  
The advantage of performing full haplotypes phasing – instead of individual genes 
brings important critical information to overcome the complexity inflicted by the 
unique LD pattern and genetic properties of the HLA region. With a facilitated 
imputation of HLA alleles, as compared to GWAS data, NGS performs more 
functionally relevant association studies at the amino acid level (55). Consequently, 
the causative variants/loci of many HLA-linked diseases will be discovered by 
complete sequencing approaches that are accessible by NGS. 
The HLA complex is a frequent hit in genome-wide association studies (GWAS) 
and has been linked with many immune-related diseases than any other region of 
the human genome (56). The sequencing resolution up to allele-level will 
investigate the influences of individual allele, haplotype, or genotype on disease 
association studies. Low-resolution HLA genotyping generates short sequences 
with high amounts of data points in each class, providing noteworthy statistical 
significance. However, an insufficient number of data points for each class, 
especially when analyzing genotype associations, can result in low statistical 
significance conclusions to reveal practical disease association effects. Alleles with 
varying effects size on disease susceptibility can conceal the precise effects of 
individual alleles. Study design should include a method that presents an adequate 
resolution to test the scientific hypotheses with an effect size ranking statistical 
method. The cost is an important part in determining the use of the genotyping 
method as higher resolution charge higher costs. HLA genotype resolution studies 
frequently vary among published literature, and the analysis of comparisons among 
genetic studies should consider that in mind.  
Through NGS, the researchers can obtain high-resolution typing data (all four 
fields) and thereby improves the full characterization of population HLA diversity, 
evolution, and demographics by several means. First, it significantly extends the 
genetic difference between populations. For this purpose, information about 
synonymous substitutions is of particular interest. These variants are prone to 
neutral evolution and maybe illuminating for the identification of demographic 
events in a specific population at an increased risk for a disease like Scandinavian 
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ethnicities with known increased risk for T1D and CD. Second, although a deep part 
of the HLA molecular distinction is concentrated in the exons encoding the peptide-
binding clefts, polymorphic sites are distributed along with the 4 Mb of the HLA 
locus, many variants located in non-coding portions of the HLA region may play a 
role in regulatory functions. Also, the neutral polymorphic sites in introns or in 3′ 
and 5´ UTR of HLA genes are beneficial for identifying regions with the lowest 
deviation from neutrality caused by the strong LD effect observed within the HLA.  
Third, large sizeable NGS-based population sequencing projects help recognize rare 
genetic variants that frequently become prevalent and contribute substantially to the 
overall allele database. The discovery of rare alleles shared by populations located 
in geographically distant regions may shed light on common origins. In Finland, the 
narrower gene pool showing HLA haplotype frequencies is well characterized by 
the Finnish population compared to European HLA alleles. The imputation success 
for HLA-DRB1 and B alleles was very low, indicating the importance of population-
specific reference database(57). Although the existing GWAS data describing HLA 
genotypes are appropriate in disease associations, it is necessary to observe that 
these tag single nucleotide polymorphisms (SNPs) are merely substitutes for given 
HLA alleles. Fourth, compared to genome-wide SNP data, NGS reads reaching all 
types of variations over the whole locus, significantly improving haplotype phasing 
and, consequently, enhancing LD estimation to assess populations' ancestry, as this 
hallmark feature decrease expectedly with time through recombination.  
The impact of NGS on genetic analysis in autoimmune disease studied is vast and 
can be compiled into two main aspects. First, NGS can target extended, in-depth 
sequencing of the HLA, particularly class II alleles DRB1, DRB3, DRB4, DRB5, 
DQA1, and DQB1. Second, HLA haplotypes analysis and molecular dissection of 
disease associations or identification of HLA‐linked causative variants (58). The 
HLA community's current efforts are directed toward the standardization of data 
reporting in HLA studies to allow comparisons among genetic predisposition 
studies (59). In the near prospect, the time may come when whole-genome 
sequencing becomes a standard measure for every individual through applying HLA 
genotyping methods and nomenclature for accurate interpretation of disease 
association studies.  
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Type 1 Diabetes (T1D) 
Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by increased 
blood glucose levels (hyperglycemia) due to the insulin deficiency that occurs as 
the consequence of pancreatic islet β-cells destruction (60). Since the early 
classification T1D issued in 1955, it is still one of the most common endocrine and 
metabolic conditions affecting children. The majority of patients have a loss of β-
cells concomitant with the formation of associated autoantibodies; herein is 
considered as autoimmune T1D. Only in a minority of patients, are autoantibodies 
not detected, and the cause of β-cell destruction is idiopathic. 
HLA gene associations with T1D 
T1D is a polygenic disease that is determined by both genetic and environmental 
factors. Genetic risk factors are required but not adequate for disease development. 
Candidate-gene studies in the early 1970s reported the first HLA association for 
T1D in HL-A antigen called previously “specificity W15” (18), assigned by new 
nomenclature to HLA-DRB1*04:01 risk allele. Afterward, Nerup et al. proved a 
subsequent association with W15 and what was then called “HL-A8” (17), which 
was named later as the HLA-B*08:01 HLA class I gene located on the conserved  
T1D risk “A1-B8-DR3” haplotype (61). Subsequent hereditary family-based studies 
replicated and confirmed these alleles risk associations (62). Studies in the 1980s 
reported the high-risk heterozygous genotype (commonly referred to as DR3/4)with 
a haplotype including DRB1*03 allele on one chromosome and DRB1*04 allele on 
the opposite by linkage analysis in families with T1D (63). Many studies have since 
confirmed that DRB1*04 as the major candidate-gene in T1D in different ethnic 
populations (64-69).  
HLA is considered the major susceptibility locus in T1D with a high likelihood ratio 
(OR of at least 6 in most studies), and accounts for approximately 40% of its 
heritability (70). The molecular structure of the HLA-encoded risk is principally 
amino acid variants in the MHC class II antigen-binding grooves that determine the 
repertory of bound antigen peptides and regulate T cell responses determining self-
tolerance and immune system activation. In T1D, the individual and additive effects 
of specific amino acid variants in HLA-DR and DQ have been subjected to extensive 
studies (71, 72). Extensive international T1D genetics collaborative studies like the 
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Type 1 Diabetes Genetics Consortium (T1DGC), worked to define genetic 
determinants in T1D and  provide resources to identify all of TID genes 
susceptibility(73). Through these efforts, the linkage to HLA-DR3 and 
DR4 established the vast majority of the genetic component of this severe life-long 
disease (74, 75). Later on, the association with the HLA-DQ haplotypes that 
include HLA-DQ2 and HLA-DQ8 for HLA-DR3 and HLA-DR4 defined the risk 
associated with these two HLA-DR risk haplotypes. Extreme genetic risk studies 
showed that the relative risk gradient is higher for HLA-DQ2 and HLA-DQ8 
homozygotes than for heterozygotes and maximal for HLA-DQ2/HLA-DQ8 
heterozygosity (76).  
DRB1-DQA1-DQB1 haplotype T1D risk associations 
Most definite HLA-associated T1D risk is thus confirmed to the HLA-DR and DQ 
encoding loci (77, 78). Because genes in the HLA region exhibit extensive LD, the 
presence of one allele allows the estimation of other alleles on the same haplotype. 
Genes encoding DR and DQ express this feature, so that, for a presented population, 
a single allele is regularly observed in only one or a few haplotype sequences given 
the known distance between them and expected recombination frequencies. This 
concept is widely studied in disease association studies. As an excellent example, 
the DRB1 gene is present in all individuals. Allelic variants of DRB1 are in LD with 
either none or one of class II DRB3, DRB4, and DRB5 genes and that make it target 
of genotyping association (79). Additionally, there are several related genes that can 
be estimated by the LD concept, like the pseudogenes (DRB2, DRB6, DRB7, DRB8, 
and DRB9).  
To explain DRB1 combination with other alleles, the DRB1*03:01 is frequently 
found linked to the DQA1*05:01 and DQB1*02:01 alleles almost exclusively, to 
form the high-risk haplotype DRB1*03:01-DQA1*05:01-DQB1*02:01, commonly 
called “DR3”. Similarity, the DRB1*04:01 is frequently found linked with 
DQA1*03:01 alleles, but it can differ in their linkage with either DQB1*03:01 or 
DQB1*03:02 to form the high-risk haplotype DRB1*04:01-DQA*03:01-
DQB1*03:01/ DQB1*03:02, referred as “DR4” haplotypes. However, the T1D risk 
for these two haplotypes is very different and that not only due to DQ-encoding 
genes driving risk for T1D or that the DRB1 locus is of limited relevance. T1D 
haplotype risk contribution comparison between DRB1*04:01-DQA1*03:01-
DQB1*03:02 and DRB1*04:03-DQA1*03:01-DQB1*03:02 haplotypes could 
point to DRB1 locus as the chief determinant of T1D susceptibility, and the DQB1 
locus is not. However, it is the total allele risk effects that most likely explain the 
combination of DR and DQ presence effect as HLA-DR-DQ accounts for ∼40% to 
50% of the overall T1D genetic risk (23, 80). Therefore, evaluating a single locus 
for T1D susceptibility can be misleading, as analysing DRB1-DQA1-DQB1 
haplotypes is considerably more appropriate. 
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GWAS, through recent landmark T1D genetic studies (77, 78, 81), not only have 
proved that single nucleotide polymorphisms (SNPs) as the most influential 
association in the DR-DQ sequence, but also reported less association of additional 
non-HLA loci (66, 82-84). Numerous studies attempted to dissect the relative risk 
confirmed by class II DR and DQ closely located loci. They extended it to the HLA-
DP locus as well (85). The findings of DRB1*03:01 allele association with the 
DRB3*02:02 allele to express an independent risk for T1D compared with the 
DRB3*01:01 allele, in which the high-risk DRB1-DRB3 haplotypes containing the 
genetic marker of DRB3*02:02 allele but also enhanced the predisposition 
for DRB1*03:01 haplotypes particularly in individuals homozygous 
for DRB1*03:01, proved the benefits of extended sequencing to DRB alleles (79). 
Specifically, on the HLA-DQ8 haplotype, HLA-DRB1*04:01 and HLA-
DRB1*04:05 are associated with greater susceptibility to T1D than is HLA-
DRB1*04:04, whereas HLA-DRB1*04:03 is shown to be protective. Several recent 
studies have attempted to distinguish the relative risk between the adjacent HLA-DR 
and DQ class II loci (80) and that extended to HLA-DP locus (85). Early T1D 
investigations showed that HLA-DQ might have more significant roles in disease 
susceptibility than HLA-DR genes (86). 
It was previously reported that HLA-DR-DQ genotypes might define various T1D 
autoimmunity response showing strong differential associations with insulin 
autoantibodies including insulin autoantibody (IAA), GAD 65 (GAD antibody ), 
IA-2 antigen (IA-2A), or the three variants (amino acids R, W, or Q on position 325) 
of ZnT8A antibodies (ZnT8RA, ZnT8WA, ZnT8QA, respectively, that can help 
develop a diagnostic tool of T1D (87, 88). In these studies, the limited analyses 
studied just HLA-DQ alleles detected by allele-specific probes (89, 90). Another 
major limitation of the referred study was the lack of typing DRB3, DRB4, and 
DRB5 alleles located between the DRA and DRB1 loci (91, 92). These haplotypes 
are often associated with insulin autoantibodies, and further studies can apply NGS 
of all DRB alleles in successively diagnosed T1D patients with all islet 
autoantibodies analyzed (93, 94) and in geographically matched control 
subjects(95). In another study, the extended haplotype HLA-DRB1*03:01-DQ2 
(HLA-DQA1*05:01-DQB1*02:01) was associated with GAD65 autoantibody (96). 
The study of patients with recently diagnosed T1D (1–34 years of age) shows that 
the age-dependent onset of T1D, which is associated with distinct HLA-DR-
DQ genotypes, is considerably related to the appearance of β-cell-targeting 
autoantibodies. These genetic risk determinants are common in western populations 
and have low penetration (97, 98), which might explain why many people do not 
develop islet-targeted autoimmunity or T1D despite having these risk factors. 
Previous T1D risk studies showed that risk depends additionally on the genotypic 
context. The total risk of the "DR3/DR4" heterozygous genotype (where either of 
the protective DRB1*04:03 or DQB1*03:01 alleles are not present in DR4 
haplotype) is higher than the total combined risk for the individual DR3 and DR4 
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homozygous haplotypes (the DR3/DR4 genotype reported having an OR of 16.6) as 
shown in a meta-analysis study (99). The proposed theoretical explanation for the 
combined risk is due to DQ heterodimers trans position (i.e., on the opposite 
chromosome) and to the DQ molecules encoding in cis position (i.e., on the same 
chromosome), on the cell surface. Each chromosome carries the DQA1 gene 
encodes an α polypeptide chain and a β polypeptide chain from the DQB1 gene.  On 
the same chromosome, both the encoded α and β chains can create heterodimers, 
and commonly the α and β chains encoded on different chromosomes can form 
heterodimers also, therefore giving the possible expression of a total four different 
DQ molecules on the cell surface. Schematically, the trans configuration of DQA1 
and DQB1 pairs were found in on a typical high-risk DR3/DR4 T1D-predisposing 
genotype. In comparison, the combination of DQA1*05:01 and DQB1*03:02 has 
not been noticed encoded in a cis arrangement, but studies showed that this 
configuration might confer a very high T1D risk (80).  
DP gene contributions to T1D risk 
The DPA1 and DPB1 genes encode the DP molecule might contribute to T1D risk. 
As mentioned earlier, because DPA1 gene low polymorphism, studies have shown 
that DPB1*03:01 (DPA1*01:03-DPB1*03:01) is associated with T1D 
susceptibility and DPB1*04:02 (DPA1*01:03-DPB1*04:02) and DPA1*01:03-
DPB1*01:01 with protection (100). Studies reported also that HLA-DPB1*04:02 
protects against T1D autoimmunity in the highest risk DR3-DQB1*02:01/DR4-
DQB1*03:02, while DPB1*03:01 and DPB1*02:02 are predisposing to T1D risk 
(101, 102). In T1D genetic association studies, LD analyses of the DR and DQ-
encoding genes on the chromosome as genetic variants of the HLA-A, B, and AIF1 
loci show independent associations (103).  
HLA class I gene associations with T1D risk 
The autoimmunity inflammatory process that leads to immune destruction of the 
insulin-producing beta-cells in the pancreas is an inflammation produced by 
cytotoxic (CD8+) T cell killing. MHC class I molecules help shape the T cell 
repertoire and present selected antigens to CD8+ T cells to initiate the cytotoxic T 
cell killing process. The role of specific combinations of HLA class I is likely to 
influence beta-cell destruction. It is shown in HLA-A*24 correlates with low 
residual beta-cell function in T1D patients (104). Many studies have localized HLA 
class I susceptibility with T1D, also combining the estimated LD with the DR and 
DQ-encoding genes (105-107). Results showed HLA-B*39:06 to have the strongest 
predisposing effect on T1D risk (OR=10.31). In comparison, HLA-B*57:01 showed 
a protective effect (OR=0.19)(107). 
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Additional studies using LD association in HLA class I with DR-DQ locus (106-
108), showed specifically the association of B*39 and A*24 alleles (68). As B*39 
has been shown to contribute risk and early onset at T1D diagnosis (106), the 
subtypes B*39:06, A*24:02, and A*29:02, incorporated into a precise genetic risk 
score (T1D GRS2) to distinguish diabetes subtypes and to prognosticate T1D in 
newborn screenings (109). The presence of the B*39:06 allele enhances the risk of 
T1D when present on distinct HLA-DR-DQ haplotypes (DRB1*08:01-
DQB1*04:02 and DRB1*01:01-DQB1*05:01) (110). By contrast, B*18 was 
associated with accelerated progression from autoimmunity to T1D, but only in 
subjects carrying DQ2, while A*24 promoted rapid progression to T1D in the 
presence of DQ8 (111).  
Many studies observed risk association of the HLA class I B*39:06 risk allele, with 
one study recommending that it can improve T1D risk prediction, particularly 
patients carrying the moderately predisposing DRB1*04:04-DQA1*03:01-
DQB1*03:02 (DR4) haplotype and HLA-DRB1∗08-DQB1∗04 haplotype (112). 
Initial studies showed HLA-A*01:01 class I allele is part of the conserved T1D risk 
recognized as “A1-B8-DR3”  haplotype, defined by using LD analysis of the HLA 
region association with T1D(61). However, A*01:01 was significantly protective 
for T1D when LD with the DR3 haplotype arranged the predicted allele frequencies 
(108). In Addition to HLA class I alleles risk effects, they can predict the age of 
T1D onset (108, 113, 114). 
Genetic associations of T1D autoantibodies 
Recent studies investigated the appearance of initial β-cell targeting autoantibody 
after childbirth changed the view of genetic risk factors. As mentioned, it is well-
known that the HLA-DR4-DQ8 and HLA-DR3-DQ2 haplotypes are the two 
principal risk contributors for T1D risk, these two haplotypes are also the critical 
risk factors for the development of T1D autoimmunity and β-cell targeting 
autoantibodies (115, 116). Furthermore, these HLA risk haplotypes might increase 
T1D development risk and can determine which type of autoantibody appears at the 
beginning (117). GAD65 autoantibody (GADA) was detected as the first β-cell-
targeting autoantibody than insulin autoantibodies in individuals with the HLA-
DR3-DQ2 haplotype. In contrast, individuals with HLA-DR4-DQ8 are more likely 
to develop insulin autoantibodies first, albeit they can develop GADA 
autoantibodies (118). The age at which autoantibody seroconversion is detected thus 
appears to be associated with these haplotypes. This finding suggests that 
individuals carrying any of these two risk haplotypes are at an increased risk of 
developing autoantibodies at a young age. Additional gene variants associated with 
T1D have also been investigated in association with the prevalence of 
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autoantibodies. T1D antibodies allele-risk associations show HLA-DQB1*03:02 
(DR4) allele is positively correlated with IA-2A, IAA, and ICA (96, 119, 120), 
whereas DQB1*02 (DR3) allele is negatively correlated with IA-2A (96, 119). In 
the case of HLA genotypes and GADA, it is found to be different according to the 
diabetes stage and the age at onset of T1D autoimmunity. Actually, the association 
of beta-cell autoimmunity with DQB1*02/*03:02 or DQB1*03:02 was shown in 
unaffected healthy children (121-123), and in young adults with late autoimmune 
diabetes onset (119) or with T1D new onset (121). 
T1D in different populations  
T1D incidence (proportion of new cases to population per year) is increasing 
worldwide, and the estimated incidence is nearly 90,000 children each year (124). 
The T1D prevalence (proportion of T1D cases to the general population) is shown 
to be the highest in the European population at approximately 1 in 300 (35). The 
incidence is highest in Scandinavian countries (such as Finland), followed by other 
European countries (such as the United Kingdom), North America, and Australia, 
while Asian countries — such as China, Korea, and Japan, T1D is considered rare 
diseases. The vast majority of T1D genetic studies have studied European descent 
subjects. The hypothesis for population risk variation remains not fully elucidated 
but may be related to genetic susceptibility and environmental and lifestyle factors, 
including personal hygiene and infections. HLA-DR-DQ genotypes also vary 
between countries (125). Although approximately 27000 HLA alleles have been 
discovered (33, 34), more than 65%% of these alleles are designated as common 
and well-documented (CWD) (126). Some common alleles, like DRB1*03:01, 
appear in almost every studied population, whereas others are population have 
specific HLA distribution. The alleles frequency distribution frequency in any 
certain population differs from other populations and usually overlaps with each 
other. For instance, HLA high-risk genotypes for T1D are common in Scandinavia 
but are less common in Asia. Still, T1D incidence estimates in kids under 15 years 
old range from as high as 64 per 100,000 per year in Finland to as low as 0.1 or less 
per 100,000 children per year in China as shown in data from the International 
Diabetes Federation.  
However, the distribution of HLA-DR-DQ haplotypes with low genetic risk in the 
original country may confer risk in children born to parents who immigrate to a 
high-risk country such as Sweden (93). Nearly 90% of children diagnosed with T1D 
in Scandinavia have one or both of HLA-DR3-DQ2 and DR4-DQ8 haplotypes (96). 
In Finnish T1D children, studies showed that DQB1*03:02 allele on the DR4 
haplotype is associated with the highest risk for T1D, especially the combination 
with the DQB1*02:01 allele on the DR3 haplotype. The DQB1*06:02 allele on the 
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DR2 haplotype is protective for T1D and found in about 36% of Finnish new-borns 
compared with about 3% of Finnish T1D children (127, 128). In Swedish studies, 
the prevalence of the high-risk genotypes DQB1*02/*03:02 and *03:02 is 
negatively associated with age at diagnosis of T1D, whereas the DQB1*06:02 
genotype has been positively associated with age at diagnosis (82, 129).  
The study population must include enough subjects to include multiple allele or 
haplotype frequencies to explain the susceptibility effect of an individual allele or 
haplotype on T1D risk. For example, unlike most DRB1*04 alleles, DRB1*04:03 is 
protective for T1D (130), but it is not easy to interpret and compare in studies of 
European populations without large-scale studies (80). Notable population 
difference is shown in DRB1*04:03 high-frequency association (3.5%) in Asian 
lineage than for subjects of European descent (0.6%) in USA (131).  
World populations are growing in the admixture, especially in the era of 
globalization. The genetic inheritance pattern is not apparent from the general 
disease phenotype, nor can it be obtained from clinical assessment. Therefore, the 
development of risk assessment modeling for all individuals, regardless of racial or 
ethnic background, requires the determination of the susceptibility attributed to 
specific alleles in extended haplotypes and genotypes readings. Genotyping DR3/4 
individual with a limited, low-resolution genetic screening test for DR, will classify 
the individual as very high risk if positive. However, both of the haplotypes are 
protective of T1D. Genotyping for both DR and DQ at two-field resolution clearly 
shows that this individual is highly unlikely to get T1D. Approximately 40% of T1D 
patients carry the DR3/4 genotype; therefore, searching for high-risk DR3/4 positive 
individuals, even for peoples of European descent, will eliminate the remaining 60% 
of the projected non-DR3/4 genotype carrier patients. The need for the study of non-
Caucasian populations to fully understand HLA susceptibility for T1D is 
emphasized. Extending the research by publishing extensive studies on non-
Caucasian, underserved, and understudied populations, as seen in the increase of 
T1D in the temporal population (56), is the best approach for complete 
understanding of HLA risk.  
Non-HLA genes in T1D 
More than 60 genetic loci have been implicated in T1D risk (65, 132-134). These 
non-HLA genes can be situated both inside and outside the HLA region. They are 
associated with immune reactions, and their associations are of far lower in effect 
than those of HLA genes; however, they have reproducible T1D autoimmunity 
effects. These genetic factors are essential to the immune system, and only a limited 
number is associated with the formation of β-cell-targeting autoantibodies (117). 
Many of these genes are associated with other autoimmune disorders. Association 
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analyses for these non-HLA genes must consider the overall nature of the HLA 
region, where LD with DR-DQ haplotypes associated with T1D can be mistaken for 
verified disease association.  
Genetic prediction of T1D 
Several comprehensive genetic screenings for T1D risk have been conducted, 
including DAISY (135), TEDDY (90), TrialNet (136) use genetic analysis to select 
subjects for following up autoantibody testing and intervention measures. T1D 
autoimmunity precedes the onset of clinical disease by months to years. Proven 
classification and use of disease-specific prevention or intervention strategies before 
the occurrence of overt disease presentation depends on the ability to identify 
prospective patients. T1D autoimmunity starts months to years before the onset of 
clinical disease. Identifying future patients is not straightforward,  and prevention is 
the ultimate goal to alter the course of the disease (137). The T1D prevention 
strategies require screening on a large scale for the high-risk population, and risk-
individuals get appropriate test intervention. These screening measures can 
significantly reduce the expense and duration of clinical studies. Therefore, HLA 
genetic testing presents a convenient screening for T1D. 
T1D prediction is becoming more attainable for risk prediction in Europeans, by 
utilizing the clinical predictive value estimated by risk score of the highest-risk HLA 
alleles with chosen single nucleotide polymorphisms (SNPs) (138). Development 
of risk score to disease susceptibility is a feasible strategy (139). A recent risk 
assessment model used 67 (SNPs) to incorporate HLA alleles, their interactions, and 
recently discovered non-HLA loci in T1D genetic risk score (termed the “T1D 
GRS2”) for proper classification of diabetes subtypes and T1D prediction in new-
born screening studies (109). Risk Predicting by analyzing different HLA alleles 
and haplotypes is also necessary to construct valid predictive models that include 
different populations.  
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Celiac Disease (CD) 
CD is a systemic immune-mediated condition triggered by gluten ingestion in 
genetically susceptible individuals and characterized by enteropathy, ranging from 
intraepithelial lymphocytosis (IEL) to total villous atrophy. The clinical 
presentation comprises a broad spectrum of features from gastrointestinal symptoms 
of diarrhea and weight loss to extra-intestinal manifestations, including iron 
deficiency anemia, bone loss, and neurological symptoms to no symptoms. 
Described for the first time in the first century before Christ, the understanding of 
CD has profoundly developed aided by the advances in epidemiological, clinical, 
and genetic research that have led to a better knowledge of the pathogenesis of the 
disease (140). The identification of CD associated antibodies, mainly those directed 
against tissue transglutaminase (tTG) (also named type 2 transglutaminase, TG2) 
(anti-tTG or anti-TG2 antibodies) and anti-endomysium antibodies (141), the 
characteristic histological features of intestinal mucosa from duodenal biopsies, the 
strong association with HLA-DQ2 and/or DQ8 in genetic analysis, and improvement 
after the introduction of a gluten-free diet (GFD) (142) constitute the hallmarks in 
CD diagnosis (143). 
The etiology of CD was not completely understood until the Dutch pediatrician 
Dr.Dicke found the association between intake of cereals and severe malabsorption 
syndrome in children (144). Later studies revealed that it is the protein gluten, a 
protein-rich in prolines and glutamines, present in wheat, barley, and rye that drives 
the inflammation in the gut. Studies of CD familial nature using small intestine 
biopsies in the 1960s established the hereditary characteristics (145). The familial 
tendency in CD directed researchers to the study of genetic markers. Initial studies 
of HLA hinted a relationship with HL-B 8 (19), and later more specific associations 
showing a very much higher prevalence of A1 and B8 in CD than in control 
populations (20). However, it is clear that although a vast majority of CD has these 
antigens, the genetic was not universal, and also, a substantial minority of non-
celiacs has them. CD was thus not ascribable fully to these markers (146). Studies 
also suggested that non-HLA genes might share responsibility, and some indicated 
that a distinct haplotype might have a negative association with CD (147).  
The impact of deamidation (addition of amino-functional group in post-translational 
modification) has been revealed through studies of T cell recognition in CD, where 
the disease-associated HLA-DQ2.5 and DQ8 molecules present gluten-derived 
peptides (gliadins) that have been deamidated by TG2 (148). Gliadins are bound to 
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HLA-DQ2.5 with high kinetic stability that leads to their sustained presentation, 
which is a requirement for the generation of the pathogenic T cell response. By 
contrast, HLA-DQ2.2 confers a low risk of CD, and its geometry is such that gliadins 
cannot be stably accommodated in the peptide-binding cleft(149, 150). The CD 
associated HLA-DQ8 lacks an aspartic acid residue at position β57, which creates a 
positively charged P9 pocket with an affinity toward negatively charged peptides 
(151). In CD, the deficiency of aspartic acid may adequately accommodate 
deamidated gliadins and may promote the recruitment of cross-reactive TCRs that 
carry a negative signature charge in CDR3β, which can respond to both the modified 
and unmodified gluten peptides (151). The deficiency of aspartic acid may 
adequately accommodate deamidated gliadins and may promote the recruitment of 
cross-reactive TCRs that carry a negative signature charge in CDR3β, which can 
respond to both the modified and unmodified gluten peptides (151). In chronic 
conditions, the range of epitopes driving pathological responses may change by 
epitope focusing, which is when T cell clones that directed against 
immunodominant epitopes outcompete other clones as reported in gluten response 
directed toward multiple gliadin and glutenin peptides (152). Thus, antigenic 
diversity in the context of polymorphic HLA molecules can promote the evolution 
of the T cell repertoire, from the early events that occur in the thymus during the 
establishment of central tolerance through to the events that occur throughout a 
lifetime in the periphery.  
Nevertheless, the ingestion of gluten does not necessarily cause CD. Only around 
1% of individuals in Western populations develop CD despite a widespread 
consumption of cereals. Furthermore, patients with CD present very differently with 
a broad spectrum of clinical manifestations at different ages of onset and variations 
in the severity of the mucosal lesions. The individual genetic background, most 
likely interacting with other environmental triggers, is seemingly contributing to 
this variability. 
Genetic risk in CD 
CD carries a strong genetic component, which has been demonstrated by 
epidemiological studies of siblings, showing a concordance of around 70–85% in 
monozygotic twins compared to approximately 20% in dizygotic twins (7, 11). 
Through familial aggregation studies, the risk of a patient's sibling to develop CD 
(relative sibling risk) is estimated at 20–60% CD (153, 154). The CD is considered 
a complex genetic disorder with genetic and environmental factors that likely 
contribute to disease to have high heritability and strong HLA association (155). It 
is considered a polygenic disease with an intricate non-Mendelian pattern of 
inheritance, involving HLA and non-HLA genes, which collectively contribute to 
the genetic risk of developing the disease. The evidence of a strong genetic 
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association reflects the central role of CD4+ T cells and the contribution of particular 
HLA molecules associated with CD in binding with specific gluten peptides that 
activate the T cells response (156). The identified genetic variability is estimated to 
be responsible for approximately 54% of the heritability in CD as reported (157, 
158) of which associated HLA-DR-DQ risk genotypes account for 53% of the 
genetic risk using recent prevalence estimates (12).  
Further investigation of the DRB3, DRB4, DRB5, and DRB1 haplotypes concerning 
DQ remains mostly incomplete, and research in this field is expanding (159). Many 
previous studies have assessed the risk associated with different HLA genotypes 
using statistical methods based on case‐control studies (160, 161). The genetic risk 
still constitutes a substantial part of the inheritance, and the need for further genetic 
association studies to reveal additional heritability factors are required. 
The population prevalence of CD is about 1/91 and heritability is estimated to be 
87%, the influence of shared environmental factors to 12%, and the contribution of 
the unshared environmental component of variance at the 1% level (7). In a register-
based twin study of CD cases, the heritability of diagnosed CD was estimated at 
75% (55% to 96%), and the non‐HLA heritability contributed to 68% (40%‐
96%)(155, 162). Surprisingly, the HLA loci only account for an additional 6% of 
the heritability of the diagnosed CD. A possible reason for the low estimate could 
be that the HLA alleles were estimated from population frequencies and not 
genotyped(163). Further exploring the unexplored heritability of CD and including 
extended HLA genotyping will conceivably reveal additional HLA alleles outside 
the DR‐DQ region in the population carrying the genetic peril. 
HLA class II genes in CD 
The strongest and best-characterized genetic susceptibilities in the CD are HLA 
class II genes, known as HLA-DQ2 and DQ8. Overall, HLA-DQ2 and DQ8 are 
present in almost 40% of the Swedish population, whereas only approximately 1% 
of the population is diagnosed with CD (164), meaning that other factors besides 
these genes are implicated in disease progression. In the 1980s, the alleles-
encoding HLA-DQ2 were identified as the main factors responsible for the genetic 
risk conferred by the HLA genes (156, 165), which had been previously attributed 
to the HLA-B*8 and HLA-DR3 alleles  (19, 166). HLA-DP alleles were reported to 
be associated with CD risk in 1989 (167) and HLA-DPB1*04:01 has been suggested 
to decrease the risk to develop anti-TG2 antibodies among DR3-DQ2 positive 
children (168). The following series explains the studies HLA genetic associations 
with CD. 
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HLA-DQ2.5 
About 90% of CD patients carry alleles encoding HLA-DQ2(169), explicitly, HLA-
DQ2.5 encoded by the DQB1*02 and DQA1*05 alleles, which can be inherited in 
cis (in the presence of HLA-DRB1*03) or trans configuration. Less than 1% of CD 
patients lack these HLA-DQ2.5 haplotypes (169). The resulting cis and trans-HLA-
DQ2.5 molecules differ in residues, which are not required in peptide identification 
(one residue in the leader peptide in the α-chain and one residue in the membrane-
proximal domain in the β-chain) and are described as conferring similar risk. These 
genetic configurations are similarly associated with CD (170). The frequency of 
HLA-DR3–DQ2 homozygosity conferred the highest risk of CD autoimmunity and 
prevalence in countries including the United States, Finland, Germany, and Sweden 
and was associated with the earliest CD onset as TEDDY study showed the CD risk 
in children with DR3–DQ2 homozygosity was increased by more than 2.5 times 
compared with the children group with a single DR3–DQ2 haplotype and more than 
five times that in the lowest-risk groups that was studied (DR4–DQ8 homozygotes 
and DR4–DQ8/DR8–DQ4 genotype)(171).  
In addition to the increased risk of developing CD in patients encoding two 
permissive heterodimers, e.g., being homozygous for DQ2.5, are at risk of 
developing a more severe CD phenotype (172, 173) with earlier disease onset, 
diarrhea, anemia at presentation, more profound villous atrophy by histology (174), 
and a slower rate of villous healing on a GFD (175), and a higher rate of refractory 
(non-responsive) CD and enteropathy-related T cell lymphoma (176). This “HLA 
gene dose” effect is supposed to be related to an increased presentation of gluten-
derived peptides by DQ2.5-homozygous individuals and used in stratifying risk for 
CD in a large at-risk population (177). 
HLA-DQ8 
Besides DQ2.5, there is an HLA-DQB1*02 gene dosage effect encoded by the 
DQB1*03:02 and DQA1*03 alleles. The denotation of “8” is not apparent in either 
of these alleles because several DQ3 variants are recognized differently by serology. 
Therefore, the DQ3 group was “split” into DQ7, DQ8, and DQ9 proteins, encoded 
by DQB1*03:01, DQB1*03:02, and DQB1*03:03 alleles, respectively. 
Importantly, only the DQ8 protein, encoded by the DQB1*03:02 alleles, is 
approved for CD and is present in approximately 20% of patients with CD (171). 
Earlier studies showed that when both progenitors inherit this allele, the risk of 
developing CD is higher than when the child inherits this allele from only one of the 
two progenitors (166). This pattern of inheritance is conditioned to the presence of 
at least one copy of HLA-DQA1*05. Most of the remaining patients not carrying 
HLA-DQ2.5 carry DQA1*03 and DQB1*03:02 , encoding the HLA-DQ8 molecule 
(178). A similar “gene dosage” effect for HLA-DQ8 was also proposed (169). In 
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nearly all CD patients who carry neither HLA-DQ2.5 nor HLA-DQ8, one of the two 
alleles encoding HLA-DQ2.5 is present: most commonly DQB1*02 (HLA-DQ2.2) 
and less commonly DQA1*05 (HLA-DQ7.5)(169).  
HLA-DQ2.2 
HLA-DQ2.2 heterodimer share similarities with DQ2.5 heterodimer, except that 
DQA1*02 allele, encodes the DQα chain, instead of DQA1*05 allele in DQ2.5. 
Although the resulting “2.2” heterodimer is significantly less able to presenting 
gluten-derived peptides compared with the 2.5 heterodimers (179, 180), most celiac 
patients without DQ2.5 or DQ8 (approximately 5%) encode the DQ2.2 heterodimer 
(181). However, patients encoding either DQ2.5 or DQ8, can carry DQ2.2 
heterodimer. The hereditary hazard conferred by these described HLA variants 
ranges from the most significant effect of HLA-DQ2.5 to no effect attributed to 
HLA-DQ7.5. However, the role of HLA-DQ7.5 in CD should be considered since 
this variant is present in nearly all CD patients lacking the known HLA associated 
risk variants. Risk factors in HLA-DQA1 and HLA-DQB1 account for 22% of CD 
heritability (182). Recent HLA region fine mapping using high-density imputation 
have identified five new CD risk independent variants in this region: HLA-DPβ1 
(position 9), HLA-B (the classical HLA-B*08 and HLA-B*39:06 alleles) and two 
SNPs, rs1611710, which shows a cis-eQTL effect on HLA-F expression, and 
rs2301226, which shows a cis-eQTL effect on B3GALT4 and HLA-DPB1 
expression (182). These five factors explain an additional 2.5–3% of the disease 
heritability. Nevertheless, the HLA-DPB1*04:01 alleles may be in linkage 
disequilibrium with risk alleles in HLA-DQ genes, and further studies are required 
to reinforce the independence between those association signals.  
HLA class I genes in CD 
The HLA class I complexes function of peptide binding and presentation to form 
the T-cell supply in the immune system is fundamental for antigen-specific T-cell 
mediated cytotoxicity, explaining the genetic association of this immunological 
reaction. HLA class II genes strong genetic association and the identification of 
several DQ2.5/DQ8 restricted gluten epitopes, explicitly recognized by CD patients, 
highlight the critical role of adaptive immunity mediated by CD4+ T lymphocytes 
in CD pathogenesis (3, 4). However, the massive infiltration of CD8+ T lymphocytes 
in the epithelium and lamina in the immune response is one of the main features of 
all states of CD pathogenesis, as seen in silent, active, or even refractory CD form. 
As discussed earlier, the primary genetic link of HLA with CD is with HLA class II 
DQA1*05/DQB1*02 genes, the earliest genetic studies performed in the 1970s of 
HLA class I association with CD revealed associations with the A*01 and B*08 
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alleles (21). GWAS fine mapping of the HLA region explained an additional 18% 
of CD heritability, independent of the DQ region, and identified B*08:01 and 
B*39:06 alleles in strong LD with the DR3-DQ2.5 haplotype (182). 
Furthermore, GWAS of the HLA region identified additional risk regions 
independent of the HLA DQA1*05 and DQB1*02 genes, among them, the HLA-
B*08:01 allele, in strong LD with DR3-DQ2.5 genes, contributes to genetic 
susceptibility to CD (183). It is reported that A*01:01 and B*08:01 influence the 
immune response by confining the adaptive CD8+ T cell responses to gluten in 
subjects with CD (184).  
Non-HLA genetic risk factors 
It has been estimated that the 6 identified HLA and 57 non-HLA genetic variants 
explain around 31% of CD heritability. It is worth mentioning that non-HLA 
variants have been estimated to account for 6.5% of the CD heritability, mainly 
explained by the classically known MHC variants. Furthermore, up to now, multiple 
common variants with low effect (except the MHC variants) seem to be responsible 
for the most significant part of this known heritability, as it corresponds with the 
polygenic disease. The contribution of non-HLA genes to CD risk susceptibility is 
much less substantial (OR < 1.5) compared with the HLA-associated haplotypes 
risk effect (OR >5), and the collective significance in the total risk effect of these 
non-HLA variants is relatively modest, estimated to account for ~15% of the genetic 
risk (185). Overall, all the genetic variants identified to date, including HLA, explain 
only ~50% of the genetic variance in CD, and additional hereditary factors may 
potentially exist that await identification. Recent association studies showed that 
more than 70 candidate risk genes in over 40 non-HLA loci had been linked to CD 
heritability (158, 182, 186-189). These non-HLA loci encode proteins implicated in 
a series of immune process including stimulating T and B cell, cell migration, 
chemokine receptor activity, cytokine binding, thymic differentiation of CD4+ and 
CD8+ T cells, and innate immunity. Only one gene is gut-specific (RGS1), 
underlining the systemic character of immune dysregulation in CD (158). No 
current evidence for specific alleles encoding gastrointestinal proteases or tTG 
explaining frequent CD co-occurrence and considerable overlap between genetic 
risk factors with other autoimmune diseases such as rheumatoid arthritis, multiple 
sclerosis, and T1D (190, 191). Despite that, the overlap between CD genetic risk 
loci and inflammatory bowel disease such as Crohn's disease has been documented 
despite the weak clinical correlation (192, 193). Interestingly, 90% of the identified 
risk loci ,critical for CD susceptibility, are located in non-coding regions such as 
promoter regions, enhancers, or non-coding RNA genes, suggesting the importance 
of gene expression regulation rather than changes at the protein-coding level (194). 
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CD in different populations  
The frequency of the CD-predisposing HLA haplotypes varies worldwide, but 
notably, CD prevalence varies in populations with a similar HLA background. Such 
diversity in CD prevalence may be explained by environmental factors rather than 
genetics. Potential environmental factors include the consumption of gluten-
containing cereals (195), infection in the early years of life (196), lower economic 
status, and a substandard hygienic environment. There are numerous studies in the 
literature focused on the incidence of HLA-DQ in patients diagnosed with CD. In 
most of these studies, HLA-DQ was evaluated, and in some studies, only HLA-DQA 
or DQB alleles were evaluated. HLA-DQ 2.5 has a high frequency in north and west 
Europe and portions of Africa, while DQ8 has a broader distribution, particularly in 
Central and South America.  
European Genetics Cluster results on CD patients recruited from Finland, France, 
Italy, Norway, Sweden, and the UK, showed a distribution between 89.4-96.7% for 
HLA-DQ2 and/or HLA-DQ887-93.7% for HLA-DQ2 and 5-8% for HLA-
DQ8(169). In Spain, the determined prevalence was 95.6% for HLA-DQ2 and/or 
HLA-DQ8, 93.4% for HLA-DQ2 risk and 2.4% for HLA-DQ8, and (197). An Indian 
study showed a 100% prevalence of HLA-DQB1*02:01, whereas the DQ2 occurred 
in 97.1% of CD patients (198). A study in Turkey found HLA-DQ2 in 67% and 
HLA-DQ2 and/or HLA-DQ8 in 76% (199). A Swedish birth cohort study showed 
that HLA genotyped more than 70% children born in the Skåne region, South of 
Sweden showed that HLA-DQB1*02 and DQB1*03:02 alleles occurred in 56.8% of 
the general population of which CD was exclusively detected in children having any 
of these two alleles (200). The comparison of all these studies reveals that the studies 
evaluating HLA-DQ haplotype and HLA-DQB1 allele are almost comparable. All 
these genetic analyses confirm variability of CD incidence across various 
geographical regions in presence HLA-DQ8. 
According to the data originating from western countries, the percentage of negative 
HLA-DQ2 and HLA-DQ8 CD patients can reach 10%, but there are also other 
studies reporting contradicting higher percentages. A study conducted in Chile 
reported that 62.9% of patients were HLA-DQ2 and DQ8 negative (201). A cohort 
study from the south of Italy found that 4.2% of CD patients were DQ2/DQ8 
negative and DQ7 was the most frequent haplotypes in all CD patients and 
significantly less frequent in DQ2/DQ8 positive CD patients (24%) than in 
DQ2/DQ8 negative patients (38%)(202). These results show that the incidence 
of CD varies independently to HLA-DQ2 and DQ8 negative among different 
populations, and DQ7 play as an additive or independent CD risk haplotype. 
Furthermore, the negative predictive value is frequently attributed to the absence of 
HLA-DQ2 and DQ8 in subjects at risk of CD.  
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Overlap of CD and T1D  
Patients with T1D and CD patients are at a higher risk of developing other 
autoimmune diseases, partially explained by shared genetics (203). It has been 
reported that between 10-30% of T1D (204) and 35% of CD patients (205) develop 
a second autoimmune disease, which is partially due to active screening of patients 
with other organ‐specific autoantibodies (206). Still, the risk is considered to be 
higher than in the general population. A Danish epidemiological study showed that 
the prevalence of autoimmune diseases was 16.4% among CD patients compared 
with 5.3% in the general population in 2016 (207). In particular, the presence of 
either T1D or CD appears to enhance the risk of developing the other disease in the 
same individual. Both diseases share common risk factors in genes, environmental, 
and immune dysregulation mechanisms. Approximately 5% of patients with CD 
have T1D diagnosis, and ~6% of T1D patients have a CD diagnosis (208, 209). 
Generally, the hypothesized causes for T1D occurrence with CD include shared 
HLA genetic risk (190, 210, 211) or shared environmental conditions (212, 213). 
Other studies suggest that double disease co-occurrence is difficult than it can be 
described by shared genetic risk loci only (214). Another plausible explanation for 
this difference in prevalence could be regional differences in extended HLA class II 
risk genotypes for the two autoimmune diseases.  
T1D w/CD epidemiology 
Walker-Smith first described the coexistence of T1D-CD in 1969 (215). While the 
CD prevalence is 0.3% to 1% in the general population of all ages (216), its 
weighted pooled prevalence was 5.1% in patients with T1D (217). The CD 
occurrence in T1D patients is 5–7 times more common than the overall population. 
4% -9% of the T1D patients have been diagnosed with CD, compared with 1% CD 
incidence of CD in the general population (218). CD occurs in 3-16% of patients 
with previously diagnosed T1D (208, 219). Conversely, individuals with prior CD 
are at a three-fold increased risk for T1D before the age of 20 (220). The risk of 
developing both diseases is thus significantly higher than that of the general 
population, which is suggested to be partially explained by shared genetics (213, 
221). CD in T1D patients is commonly asymptomatic or slightly symptomatic, and 
the diagnosis is reached through the routine screening. The hypotheses behind the 
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CD prevalence has been portrayed as a model of an "iceberg," where the 
asymptomatic cases represent the bulk of the iceberg that is not noticeable and 
symptomatic cases represent only the visible tip of the iceberg. Thus, the hidden CD 
prevalence is hypothesized to be the bottom layers of the CD “iceberg”. In most 
subjects, the diagnosis of T1D precedes the development of CD, while it is less 
likely cases with double diseases are diagnosed simultaneously. In many cases, the 
CD is approximately diagnosed within two years after diabetes presentation (222). 
Although approximately 11% to 25% are diagnosed with CD first (217), most 
epidemiological studies have investigated T1D patient's risk for developing CD. 
Recent epidemiological studies from different countries that are mainly wheat 
consuming showed higher T1D w/CD prevalence rate including Saudi Arabia 
(11.3%), Denmark (10.4%), Sweden (9.67%), Canada (7.7%), Italy (6.65%), and 
Iran (6.2%) (222-227). In comparison, lower coincidence rates are seen in other 
countries from Tunisia (5.3%), Austria (5%), Australia (5.7%), United Kingdom 
(4.42%), and Egypt (4%) (228-232). All these epidemiological estimates have been 
described for cleared biopsy-proven CD cases, confirmed by serological screening 
with autoantibodies. Consequently, these figures represent the classically diagnosed 
CD incidences and lack the estimation of latent or silent CD forms.  
 
Genetics in patients with T1D w/CD 
Studies showed that shared genetic predisposition to both T1D and CD is attributed 
to being homozygous for HLA-DQ2 or heterozygous for DQ2.5/DQ8, of which the 
latter genotype seem to predispose patients to develop both diseases (233, 234). 
Although both diseases are also associated with HLA class I gene variants as 
discussed previously (67, 235), there is a paucity of genetic epidemiology studies 
on patients with T1D w/CD.    
Possibly this shared genetic overlap might be the primary factor leading to the 
concomitant occurrence of T1D and CD. Reasons for concurrent CD and T1D 
include shared HLA genetic risk (190, 211, 236) and shared environmental 
exposures.(212, 213). However, data suggest that disease co-occurrence is higher 
than can be described by shared genetic risk loci (214). Several clinical studies 
described shared risk factors and mechanisms of T1D and CD, including TEDDY 
study that found T1D usually precedes CD autoimmunity. It also found that co-
occurrence is greater than the frequency explained by demographic and genetic 
factors (214). A main finding of the T1DGC study was that common genetic variants 
contribute to T1D and autoantibodies associated with CD (237). 
Suggested hypothesis for the increased susceptibility to CD and T1D coexistence is 
the presumed presence of DQ2.5 and DQ8 heterodimers encoded by alleles in trans, 
in addition to the DQ molecules encoded by alleles in cis, on the cell surface of 
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immune cells demonstrated in two alleles in LD, DQA1*05, and DQB1*02, 
encoding the DQ2.5 molecule, and DQA1*03 and DQB1*03, encoding the DQ8 
molecule (238). Consequently, the associations of these two DR-DQ genotypes 
(DR3-DQ2.5/DR3-DQ2.5 and DR3-DQ2/DR4-DQ8) with CD and T1D indicate that 
the mechanism of autoimmune susceptibility may partly be overlapping. 
In GWAS, only three non-HLA loci were identified as related to T1D w/CD: RGS1 
on chromosome 1q31, IL18RAP on chromosome 2q12, and TAGAP on 
chromosome 6q25 (190), respectively. However, the association of these single 
nucleotide polymorphisms is weak compared to the association seen with HLA 
(190). Analysis of reported shared loci in T1D and CD show considerable variants 
overlap associated with these two conditions demonstrated in of 8 CD loci, 6 loci 
showed association with T1D as well, and over of the 17 loci associated in T1D, 8 
showed an association with CD. Many of non-HLA loci are also associated with 
other autoimmune diseases (239). 
Association of HLA genes 
Nearly all patients with T1D w/CD carry either the DRB1*03-DQA1*05:01-
DQB1*02:01 (DR3-DQ2.5) or DRB1*04-DQA1*03-DQB1*03:02 (DR4-DQ8) 
haplotypes (240, 241). As previously discussed, the DR4-DQ8/DR3-DQ2.5 
genotype is associated with the most significant risk of T1D (71) and DR3-DQ2.5/ 
DR3-DQ2.5 genotype the highest risk for CD (242, 243). Although DR3‐
DQ2.5/DR4-DQ8 and DR3‐DQ2.5/DR3‐DQ2.5 positive individuals are at higher 
risk to develop T1D w/CD than individuals carrying other HLA genotypes (244), a 
Norwegian study showed that patients with T1D w/CD have HLA profile more 
similar to T1D patients than CD patients (211). However, additional risk factors on 
the extent of developing T1D w/CD independent of known HLA class II including 
extended HLA haplotypes and non‐HLA genes are yet to be determined (244, 245). 
Although the NGS technology has facilitated the definition of full-length HLA gene 
sequences, allowing an in-depth characterization of population HLA heterogeneity 
(246), extended HLA class I allelic and haplotype diversity in T1D and CD have 
not been well studied. There are different genetic associations between patients with 
T1D w/CD, T1D only, or CD only. The result of genetic risk is based, principally, 
on particular shared alleles and genotypes in the HLA class II region, with some 
support for HLA class I that may be linked through extending the genotyping 
analysis. The HLA and non-HLA loci found in further studies can be used as 
stratification factors in the building of risk models to predict double autoimmunity. 
Previous studies were based on lower resolution (1st and 2nd field) HLA typing of 
selected HLA loci in individuals who share both diseases, providing incomplete 
insight into the HLA diversity (235). 
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Aims of the thesis 
The aim of the thesis was to test the hypothesis if subtypes of HLA-DR, DQ, and 
DP are associated with T1D, CD as well as T1D w/CD using NGS. To achieve these 
aims, four studies were conducted (Paper I-IV), each with the following specific 
aims:  
I. To test the hypothesis that HLA-DRB3, DRB4, and DRB5 alleles modify the 
risk conferred by DRB1 for islet autoantibodies and T1D genetic risk (Paper 
I). 
II. To test the hypothesis that HLA-DRB1, DRB3, DRB4, and DRB5 affect the 
risk of CD in relation to the DQA1 and DQB1 haplotypes (Paper II). 
III. To extend the findings of our two previous investigations and perform high-
resolution genotyping using high-throughput NGS technique in children 
with T1D and CD in the search for shared extended HLA class II loci in 
children that develop T1D w/CD (Paper III) 
IV. To investigate if HLA class I alleles differ between children with T1D and 
CD and if a specific HLA class I alleles contribute to disease risk in T1D 
w/CD children (Paper IV). 
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Study populations  
Paper I 
A case-control study design included nine hundred seventy patients (n=970) given 
a diagnosis of diabetes between 9 months and 18 years of age were sequentially 
enrolled from a nationwide Swedish BDD study (87, 93, 247). American Diabetes 
Association and World health organization criteria were used for the diagnosis and 
classification of diabetes. Patients included had at the time of clinical diagnosis one 
or several of T1D autoantibodies against insulin: IA-2A, and ZnT8RA, ZnT8WA, 
or ZnT8QA. Four hundred forty-eight control subjects (n=448) matched for age (1–
18 years), sex, and place of residence were analyzed at the same time (95). 
Paper II 
This case‐control study comprised of 278 patients (174 females and 104 males) 
recruited as part of the GENEX study (248). Study participants were investigated 
with an upper endoscopy with serial intestinal biopsies taken from the bulb and 
duodenum at median age 9.8 years (1.4‐18.3 years) between 2010 and 2012 at the 
Department of Pediatrics, Skåne university hospital situated in Malmö, Sweden. All 
patients serum samples were assessed at time for intestinal biopsy for both IgA and 
IgG autoantibodies against tissue transglutaminase (tTGA) using radioligand 
binding assays previously described (249).Among the 143 patients selected as cases, 
118 had untreated celiac disease, 4 treated celiac disease and 21 were persistently 
tTGA positive and classified as having potential celiac disease (Table 3). For the 
135 patients selected as controls, celiac disease was ruled out by the findings of 
intestinal biopsy and/or serology. Study groups were selected to be of Scandinavian 
ethnicity and non‐Scandinavian ethnicity based on parents’ place of birth.  
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Table 3.   
Proportion (%) of children with CD (cases) compared to non-celiac disease controls. Grading of intestinal biopsies were 
applied according to the Marsh-Oberhuber classification and a Marsh score >1 was compliant with biopsy-proven CD 
(250). 
characteristics Cases 
(n=143) 
Controls 
(n=134) 
P-value 
 
Gender  
Female 
Male 
 
71.6 
32.9 
 
58.2 
39.2 
 
<0.001 
 
Age (year) 
0- 
5- 
10- 
15-20 
 
 
6.7 
14.7 
39.6 
42 
 
 
38.1 
34.3 
15.7 
9.1 
 
<0.0001 
 
Marsh score 
M0 
M1 
M2 
M3A 
M3B 
M3C 
 
 
8.2 
9.8 
2.2 
21.7 
34.3 
26.6 
 
 
72.4 
25.2 
0.00 
7.00 
0.00 
0.00 
 
<0.0001 
 
IgA-tTGA 
Negative 
Positive 
 
 
8.2 
92.2 
 
 
 
91 
8.5 
 
<0.0001 
 
IgG-tTGA 
Negative  
Positive 
 
 
9.7 
90.8 
 
93.3 
6.4 
 
 
<0.0001 
 
Papers III & IV 
Both studies III and IV used the same study subjects. Included children that were 
prospectively followed in a birth cohort that screened for T1D and CD between 2004 
and 2010 at the Unit of Diabetes and Celiac disease, Department of Clinical 
Sciences, Lund University, Malmö, Sweden, as described (251). A total of 219 
children were diagnosed with CD (137 females, 82 males, n=219) at median age 4.5 
(range 1.1-11.0 years) according to ESPGHAN criteria (252), 68 children were 
diagnosed with T1D (39 females, 29 males, n=68) at median age 5.5 (range 0.9-
11.3) years according to the American Diabetes Association criteria (253), and 
seven children (5 females, 2 males, n=7) with double diagnosisT1D w/CD . 
Representing the general population (GP), 448 healthy Swedish children (254) and 
188 healthy children randomly selected from the LifeGene prospective cohort study 
49 
were included as controls (n=636)(255) in study III were matched for high-
resolution NGS of HLA class II. 
 
Figure 7. Flow chart of study groups 
  
2525 Swedish Children 
cohort  
CD-only patients 
(N=219)  
Type 1 diabetes with 
celiac disease (N=7) 
T1D-only 
patients (N=68)  
Next generation targeted sequencing of HLA 
class II genotypes 
50 
  
51 
Methods  
Laboratory Methods 
DNA Extraction 
CPT™ (Cell preparation Tubes) was used for blood collection from patients and 
controls at assigned clinical localities. After collection, CPT was sent to the 
laboratory for DNA extraction. After centrifugation, blood was phased into layers, 
plasma on top, a cloud of mononuclear cells above the gel-component in the tube, 
and the dense bottom layer of red blood cells. This granulocyte containing layer at 
the bottom of the tubes was used for DNA isolation using The Plasmid Maxiprep 
Kit (QIAGEN) according to the manufacturer’s instructions (Qiagen, Hilden, 
Germany) from frozen whole-blood samples of patients and control subjects. 
Islet Autoantibodies 
Paper I included quantifications of  insulin autoantibodies including GADA, IA-2A, 
IAA, and the three variants of ZnT8A (ZnT8RA, ZnT8WA, or ZnT8QA) that were 
determined in quantitative radiobinding assays by using in-house standards to 
determine biochemical levels as previously described in detail in previous studies 
(247, 256). 
HLA High-resolution NGS analysis 
HLA high-resolution sequencing of both class I and II was performed with the 
ScisGo HLA v4.0  typing kit of the genotyping system according to the 
manufacturer’s instructions (Scisco Genetics Inc., Seattle WA, USA) using MiSeq 
v2 PE500 (Illumina, San Diego, CA)(53, 54, 257). Robust assays for each target 
loci of all class I & II loci were used providing a depth of genotyping extending. 
The principle behind NGS technology is DNA polymerase catalyzes the 
incorporation of fluorescently labeled deoxyribonucleotide triphosphates (dNTPs) 
into a DNA template strand during sequential cycles of DNA synthesis. During each 
cycle, at the point of incorporation, the nucleotides are identified by fluorophore 
excitation. NGS extends the process across millions of fragments in a massively 
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parallel fashion. It delivers high accuracy, a high yield of short error-free reads, and 
a high percentage of base calls above Q30 than methods with long reads. 
Illumina NGS workflows include four serial steps: 
1. Target generation: PCR amplification of specific HLA loci to generate a large 
amount of target DNA. Longer amplicons copies “PCR product” are produced, 
and DNA concentration is calculated. 
2. Library Preparation: Three sequential steps prepare the sequencing library; 
random fragmentation of the DNA or cDNA sample, followed by 5′and 
3′adapter ligation and finally, Barcoding or “tagmentation” that combines the 
fragmentation and ligation reactions into a single step that significantly 
increases the efficiency of the library preparation process. DNA fragmentation 
is a random process, which guarantees that shorter overlapping sequencing 
reads encompass the complete gene. Enzymatic cleavage is directly followed 
by DNA repair and A-tailing in a common reaction. Adapter-ligated fragments 
aim to add primers to the end of the DNA fragments to enable sequencing. The 
fragmentation process forms DNA fragments with A-overhang; adaptors come 
with T-overhang to enable ligation. Illumina NGS later uses the sequences of 
adaptors. Following adaptor ligations is DNA cleaning and size selection. This 
step removes components that could eventually interfere with sequencing. 
Selection with SPRI (Solid Phase Reversible Immobilization) beads aim to sort 
larger fragments, which is preferable in the later process of phasing. Barcoding 
enables samples from different individuals to be pooled and run in single 
sequencing analysis. Indexing PCR is performed as each fragment is elongated 
to contain individual barcodes and flow cell attachment sites. The resulting 
library-pooled sample includes DNA from several individuals and loci.   
3. Cluster Generation: For cluster generation, the library is loaded into a flow 
cell where fragments are captured on a lawn of surface-bound oligos 
complementary to the library adapters. Each fragment is then amplified into 
distinct, clonal clusters through bridge amplification. When cluster generation 
is complete, the DNA templates are ready for sequencing, each including copies 
of the same DNA fragment. 
4. Sequencing: Sequencing-by-synthesis is sequencing technology used primarily 
by Illumina, in which a DNA polymerase synthesizes a strand of DNA 
complementary to a template by incorporating a fluorescently labeled 
deoxynucleoside triphosphate that is imaged to identify the base and then 
cleaved before the process is repeated to determine the order and identity of 
each base in the DNA strand. It employs a proprietary reversible terminator–
based method that detects single bases as they are incorporated into DNA 
template strands. As all four reversible terminator–bound dNTPs are present 
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during each sequencing cycle, natural competition minimizes incorporation bias 
and significantly reduces raw error rates. The result is highly accurate base-by-
base sequencing that virtually eliminates sequence context-specific errors, even 
within repetitive sequence regions and homopolymers. 
Data Analysis 
During data analysis and alignment, the newly named sequence reads are aligned to 
a reference genome. Following alignment, many variations of HLA analysis are 
potential, such as single nucleotide polymorphism (SNP) or insertion-deletion 
(indel) identification, read counting for DNA methods, phylogenetic or 
metagenomic analysis. HLA typing results for the new samples are analyzed using 
known sequences by software analysis. 
In short-read sequencing by Illumina technology, DNA fragments are ligated to 
adapters. The adapters contain unique molecular identifiers as well as sequences 
complementary to the oligonucleotides attached to the surface of a flow cell. 
Adapter-tagged DNA is loaded onto a flow cell, and the adapters from the modified 
DNA hybridize to the oligonucleotides that coat the surface of the flow cell. Once 
the DNA fragments have attached, cluster generation begins, where thousands of 
copies of each fragment are generated through a process known as bridge 
amplification. In this process, one strand folds over, and the adapter on the end of 
the molecule hybridizes to another oligonucleotide in the flow cell. A polymerase 
incorporates nucleotides to build double-stranded bridges of the DNA molecules, 
which are subsequently denatured to leave single-stranded DNA fragments tethered 
to the flow cell. This process is repeated over and over, generating several million 
dense clusters of double-stranded DNA. After bridge amplification, the reverse 
DNA strands are cleaved and washed away, leaving only the forward strands. Then, 
sequencing by synthesis begins, in which fluorescently labeled deoxynucleoside 
triphosphates are incorporated into the newly synthesized DNA strand at each cycle. 
After incorporation, a laser excites the fluorophore on the strand, emitting a 
characteristic fluorescence signal that corresponds to the base.  
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Statistical Methods 
Paper I  
The project was performed to determine allelic association analysis of the 
multiallelic genes of HLA-DRB1, -DRB3, -DRB4, and -DRB5 in the diabetes group 
(n=970) and control subjects (n=448). Under Hardy-Weinberg equilibrium, the 
allelic analysis computes allelic frequencies among patients only, control subjects 
only, and the combination of both by calculating sets of alleles of varying frequency, 
effect size and direction that disrupt the same gene. Given excessive HLA 
polymorphism, a score test used test allele-specific associations with T1D (258, 
259). The score test estimates the allele-specific arrangement following the null 
hypothesis with no allelic associations and is referred to as the H-score because it 
was particularly developed for testing haplotype associations. Under the null 
hypothesis, H-score has an asymptotic normal distribution, which is utilized to 
calculate the P-value. The statistical approach was to consider all potential 
haplotype combinations for ambiguous HLA data. For all estimates, we used the R 
function haplo.cc found on (http://cran.r project.org/web/packages/haplo. 
stats/index.html). The function haplo.cc computes the haplotype-based association 
used for the haplotype analysis described next and assesses the allelic association 
by introducing a monomorphic locus as the second locus. The algorithm estimates 
the likelihood probability by counting all compatible haplotypes by the frequency 
of haplotypes pairs. The significance of individual haplotype effects was estimated 
using Wald statistics. To estimate allele-specific magnitudes of the T1D association, 
we chose the reference allele with comparable allelic frequencies between patients 
and control subjects and had a relatively high allelic frequency. In comparison with 
this reference allele, we calculated the OR for every allele. The OR of the reference 
allele is given the 1 value, OR <1 implies a protective allele, and an OR >1 is a risk 
allele.  
In the HLA-DR locus, alleles of HLA-DRB1 are in LD with alleles of either HLA-
DRB3 or -DRB4 or -DRB5. Hence, by treating these subunits and their allelic 
variations as different alleles, analysis of HLA-DRB1 and -DRB3, -DRB4, or -
DRB5 by haplo.cc produces estimates of frequencies for all haplotypes provided 
that expectation numbers of corresponding haplotypes are five or more copies in 
both patients and control subjects. Similarly, the function haplo.cc produces H-
scores and P values for all included haplotypes. By following the same principle of 
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choosing the reference haplotype, we computed haplotype-specific ORs. A two-
dimensional table was created to facilitate the understanding of estimated 
haplotype-specific ORs by showing H-scores for specific pairs of alleles at HLA-
DRB1 and -DRB3, -DRB4, or -DRB5.  
Paper II  
A frequency matching strategy, matching cases, and controls by gender was applied 
in Paper II. Allelic association analysis of multiallelic genes of HLA-DRB1, DRB3, 
DRB4, DRB5, DQA1, and DQB1, was performed. Alleles of DRB3, DRB4, and 
DRB5 at the DR locus do not jointly reside on the same chromosome. These 3 genes 
are assigned as a “single gene” DRB345 for the analytic facilitations. For each gene, 
allelic frequencies were computed among cases, controls, and combined cases and 
controls, under the Hardy Weinberg equilibrium. To test if the allele is significantly 
associated with CD, the same allele-specific in Paper I score test was applied(258). 
The H-score test evaluates the allele-specific score under the null hypothesis with 
no allelic associations and it was developed specifically for testing haplotype-
association. H score has an asymptotic normal distribution, which is then used to 
compute P-value under the null hypothesis.  
To retain meaningful interpretation on allele-specific odds ratios, it is estimated that 
under the null hypothesis for a reference allele, its allelic frequency in cases should 
be comparable to that in controls, and thus their ratio equals 1. In comparison with 
this presumed reference allele, odds ratios were calculated marginally for every 
allele as the ratio of allelic frequency in cases over that in the controls, that is, the 
ratio of exposure rates (RR). RR of less than 1 implies a protective allele, and RR 
of greater than 1 is a risk allele. Within the DR locus, alleles of DRB1 are in linkage 
disequilibrium with alleles of DRB345. 
Similarly, DQA1 and DQB1 are in high LD with each other in the DQ locus. 
Further, DR and DQ loci are physically adjacent to each other, and many of their 
alleles are highly associated with each other. Since phases of these individual genes 
are incomplete, statistically driven haplotype analysis on DRB1-DRB345, DQA1-
DQB1, or DR-DQ was performed. 
Without assigning haplotypes directly, the statistical approach is to enumerate all 
possible haplotype configurations with empirically computed prior probabilities and 
produces estimates of haplotype frequencies for all possible haplotypes, provided 
that expectation numbers of corresponding haplotypes are 10 or more copies in the 
combined cases and controls. Just as those statistics produced for allelic association 
analysis, haplotypic frequencies were computed among cases, controls, and pooled 
case-control. Then, the function “haplo.cc” produces H-scores and P-values for all 
included haplotypes. Following the same principle of choosing the null reference 
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haplotype, in other words, comparing haplotypic frequencies between cases and 
controls, the haplotype-specific RR was computed. During the evaluation of allelic 
associations within individual genes, the bootstrap technique was used for random 
sampling with replacement to form a bootstrap sample to estimate the allele-specific 
rate of ratios (allelic frequency) among cases over controls, which is equivalent to 
odds ratio gave the assumption that 2 allelic frequencies are the same between cases 
and controls. Using 1000 bootstrap samples, we estimated associated standard errors 
and thus associated confidence intervals for individually estimated RRs.  
Paper III and Paper IV  
Allelic frequency distribution analysis of HLA-class II in paper III and HLA-class 
I genes in paper IV was determined by the relative predispositional effects (RPE) 
analysis(260). Crude odds ratios (ORs) and their associated 95% confidence 
intervals (95% CI) were calculated, and χ2 tests and Fisher’s exact tests (if any cell 
contained fewer than three observations) were used to test whether the frequencies 
of a given allele/haplotype differed between cases and non-cases. The RPE method 
was used to identify the disease risk alleles, haplotypes, or genotypes with the 
strongest predisposing or protective effects at each iteration. The selected alleles 
were then removed from the dataset, and the analysis was repeated until no risk or 
protective alleles were identified. Comparisons of DR, DQ, and DP allele 
frequencies were performed for both exons 2 and 3 of chromosome 6p21 by 
performing pairwise comparisons between all Paper III study groups and listed in 
order of increasing P-value, followed by the extended haplotype and genotype 
frequencies. Comparisons of HLA-A, -B, and -C allele frequencies were performed 
for exons 1–7 of chromosome 6p21 by performing pairwise comparisons between 
all paper IV study groups and listed in order of increasing P-value, followed by the 
extended haplotype and genotype frequencies. P-values ≤0.05 were considered to 
be statistically significant, and alleles with a low frequency (≤ 1%) were not shown 
in the analysis. The p-values presented are nominal and not adjusted for multiple 
comparisons. Analyses were performed in R (r-project.org) version 3.6.1 and R 
package epiDisplay version 3.5.0.1. 
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Results & Discussion  
Paper I: “Next-Generation Sequencing Reveal that HLA-DRB3, -DRB4, and -
DRB5 May Be Associated with Islet Autoantibodies and Risk for Childhood Type 1 
Diabetes” 
Main findings in Paper I showed first that by analyzing the 25 HLA-
DRB1 genotyped alleles, only four (DRB1*03:01:01, DRB1*04:01:01, 
DRB1*04:04:01, and DRB1*04:05:01) were found positively associated with T1D 
risk. The H-score was used to rank the relative degree of risk by decreasing order as 
follows: DRB1*04:01:01 >*03:01:01 >*04:05:01 >*04:04:01.  
Second, NGS revealed nine genotyped DRB345 alleles; eight of them are alleles 
of DRB3, DRB4, and DRB5 plus one including chromosomes with only non-
amplified loci. Only two alleles; DRB4*01:03:01 and DRB3*01:01:02 were 
positively associated with T1D risk; the remaining five alleles were negatively 
associated with the disease. DRB4*01:03:01 has a high association ranking (H-
score 12), which ranked higher than DRB3*01:01:02 (H-score 4). Another 
important finding, DRB4 alleles were divided in their risk effect in 
which DRB4*01:03:01 was positively associated and DRB4*01:01:01 was 
negatively associated with T1D as evidenced in haplotype association 
with DRB1*07:01:01. Likewise, DRB3*01:01:02 was positively associated 
and DRB3*02:02:01 negatively associated with T1D. Because either one of these 
two alleles may be shown on a haplotype bearing DRB1*03:01:01, it cannot be 
excluded that the risk of this allele for T1D is influenced by the DRB3 alleles to 
either increase or decrease the risk.  
A third finding when analyzing the extended DRB1-DRB3-DRB4-DRB5 haplotypes 
(28 haplotypes were identified), was that the two DRB1*03:01:01-containing 
haplotypes remained positively associated with T1D whether 
either DRB3*01:01:02 or DRB3*02:02:01 was shown (although the positively 
associated DRB3*01:01:02 showed a P-value for risk that was three times higher 
than for the DRB3*02:02:01-containing haplotype). More importantly, the 
borderline associations of the DRB3, DRB4, and DRB5 alleles were extensively 
affected by DRB1 alleles. The interpretations of the different extended DRB1-
DRB3-DRB4-DRB5 haplotypes strongly infer that the risk for T1D cannot be 
attributed to a single DRB1 allele but that DRB3, DRB4, and DRB5 in LD have to 
be considered when dissecting the role of HLA-DR in T1D. 
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The application of NGS method in the Paper I enabled extended DRB1-DRB3-
DRB4-DRB5 haplotypes to be calculated without information on the linear descent 
relationship. Sequencing of coding regions of exon 1–4 of 
both DRB1 and DRB3, DRB4, and DRB5 allowed the detection of all functional 
genes, whereas pseudogenes were not magnified. Despite the presence of 
pseudogenes in the DRB3-DRB4-DRB5 region, it was possible to compute full 
sequenced haplotypes without ambiguities, including in subjects with pseudogenes 
such as DRB1*01:01:01, DRB1*01:02:01, DRB1*08:01:01, and DRB1*10:01:01, 
respectively. The utilized method is a study improvement because it deducted high-
resolution typing of alleles, which has been understudied. Due to reduced costs of 
PCR, novel instrumentations and approaches in bioinformatics make NGS HLA 
typing affordable and accurate.  
The study population was appropriate because it represents coherent patients with 
lately diagnosed T1D in Sweden (87, 93). Moreover, patients in the Paper I were all 
born to parents born in the same geographic locations, as was the fact for their 
grandparents (93). According to Swedish pediatric diabetes guidelines, all patients 
with T1D <18 years old are seen by pediatricians at one of the pediatric diabetes 
clinics in Sweden. The implied vulnerability of this study is that it could not analyze 
a control group of equal numbers as the patients. However, the current control 
subjects were selected to represent the geographical location of the patients (261). 
By reviewing the literature, only one published study found analyzed the NGS 
of DRB genes (79). It included 143 control subjects and 337 patients of a much 
larger cohort and reported that both DRB3*01:01 and DRB3*02:02 alleles showed 
an increased risk for T1D. In particular, DRB1*03:01 and DRB3*02:02 contribute 
to T1D risk. By comparison, Paper I analysis of patients with newly diagnosed T1D 
and control subjects shows results compatible with the mentioned outcome. 
However, paper I results differ because DRB3*02:02 was negatively associated 
with T1D, and when considered with DRB1*03:01:01, DRB3*02:02:01 reduced 
the risk for T1D compared with the DRB1*03:01:01-DRB3*01:01:02 haplotype. 
T1D risk haplotypes containing DRB1*03:01:01 may either carry the 
DRB3*02:02:01 or DRB3*02:02:01 alleles. In the TEDDY study, 
DRB1*03:01:01/DRB1*03:01:01 homozygous children were at an increased risk 
for developing GADA as their first islet autoantibody (115). Additional studies are 
required to determine whether DRB3*02:02:01 affects the risk of GADA as to the 
first islet autoantibody (262). The negative association of DRB1*01:03 with T1D 
was independent of DRB3, DRB4, and DRB5 because it resides on a haplotype 
unqualified to express any of these DR subtypes. The analysis is that 
the DRB1 protein heterodimer confers protection, presumably by inducing 
immunological tolerance. Future studies of amino acids of HLA-DRB1 and HLA-
DRB3, 4, and 5 can include potentially causal residues responsible for the risk of 
T1D (55). 
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The significance of the results in Paper I is that DRB3, DRB4, and DRB5 may affect 
not only the risk for T1D but also the risk of having specific islet autoantibodies. 
The data strongly suggest that DRB3 on the DRB1*03:01:01 haplotype affects the 
risk of having GADA or ZnT8RA (positive association) or IA-2A (negative 
association). Patients with DRB1*07:01:01-DRB4*01:01:01 are at an increased 
risk for GADA detection at a clinical diagnosis. Therefore, determining to what 
extent the DRB3, DRB4, and DRB5 β-chains can form heterodimers with 
the DRA α-chains is significant. It cannot be excluded that peptide presentation 
on DRB3, DRB4, or DRB5 heterodimers may induce immune responses related to 
autoimmunity.  
Paper II: “Different DRB1*03:01-DQB1*02:01 haplotypes confer different risk 
for celiac disease” 
Paper II is the first study that implements NGS in HLA haplotype analysis in CD. 
The main findings showed that the highest risk haplotype for CD, DRB1 *03:01:01‐
DQA1 *05:01:01‐DQB1 *02:01:01(DR3-DQ2.5) is modified at the DRB3 locus. 
The most frequent of these haplotype among the Scandinavian population is DRB3 
*01:01:02 in linkage with DQA1 *05:01‐DQB1 *02:01 (hereafter called “8.1AH” 
for the extended ancestral haplotype HLA‐A1-B8-DRB3*01:01-DRB1*03:01-
DQB1*02:01) and the less frequent version of this haplotype carries another 
DRB3*02:02:01 in linkage with DQA1*05:01‐DQB1*02:01 (hereafter called 
18.2AH for the extended ancestral haplotype HLA‐A30-B18-DRB3*02:02-
DRB1*03:01-DQB1*02:01) (Fig 8). Even though both of these haplotypes are 
associated with CD, no patient carried the 18.2AH haplotype only.  
Second, among CD patients who carried the 18.2AH haplotype on 1 chromosome, 
all carried different CD risk haplotype (i.e. either the DRB3*01‐DQA1*05:01‐
DQB1*02:01 (DQ2.5), DQA1*02:01‐DQB1*02:01 (DQ2.2) or DQA1*05:05‐
DQB1*03:01 (DQ7.5) haplotype) on the opposite chromosome. The lack of patients 
carrying a single risk haplotype 18.2AH emphasizes that other HLA‐linked loci are 
required in the disease process. If only DQ alleles were involved, the two haplotypes 
A8.1AH and 18.2AH (identical at the DQA1 and DQB1 loci) should carry the 
identical risk.  
Third, the results of Paper II suggest that 18.2AH has a regressive conservative 
pattern of inheritance which is line with a previous Sardinian study (263). In 
discrepancy, the 8.1AH haplotype is inherited to affected individuals with an 
additive influence and often as a single risk haplotype where the opposite haplotype 
can be any other haplotype. The 18.2AH haplotype confers likely a synergistic effect 
combined with the 8.1AH haplotype in increasing the risk of CD in those individuals 
carrying homogenous variants, while the 18.2AH haplotype does not appear to 
confer risk on its own. These interpretations of the different extended DRB1‐
DRB345‐DQ haplotypes suggest that the risk of CD cannot be attributed to the DQ 
locus only.  
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Figure 8. Association result from extended analysis of HLA class II alleles to the risk of CD. 
The translation product of the DRB3*01 and DRB3*02 alleles generate class II 
heterodimer molecules with the essentially non‐polymorphic alpha (DRA) chain, 
which is essential to the immune system by introducing peptides derived from 
extracellular proteins (264). However, there is inadequate data about the functional 
role of the heterodimers formed of DRB3*01 and DRB3*02. The DRB3*02 alleles 
are critical in hepatitis virus clearance, and DRB3*02 on 
the DRB1*03:01 haplotypes contributed to an increased risk for T1D when 
compared to the DRB1*03:01/*03:01 homozygotes carrying only 
the DRB3*01 haplotype on both chromosomes (79). DRB3*02 may confer a 
synergistic effect increases the risk for T1D as well as CD in combination with 
another DRB3*01 or DRB3*02 alleles, but a potentially protective effect for CD, 
counteracting the DQA1*05:01‐DQB1*02:01 molecules except coupled with other 
HLA risk haplotypes. 
The results showed that the DQ2.5 haplotype risk can be divided into 2 distinct 
haplotypes; DRB3*01‐DQA1*05:01‐DQB*02:01 (8.1AH) and DRB3*02‐
DQA1*05:01‐DQB*02:01 (18.2AH), with a seemingly different risk associated 
with each haplotype. Unlike 8.1AH, the 18.2AH haplotype is likely to confer only 
a minimal CD risk on its own, despite being identical at the DQA1 and DQB1 loci. 
The advantage of NGS for estimating HLA‐DR and DQ polymorphism has 
presented a total of 15 novel haplotypes found to have significant haplotypic 
frequencies in a general Swedish population and allowed for deep dissection using 
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this “HLA‐omic” methodology as seen also in Paper I (265).  Although this study 
showed differences between DRB3*01‐DQA1 *05:01‐
DQB1*02:01 and DRB3*02‐DQA1*05:01‐DQB1*02:01 on the disease risk, there 
are potential shortcomings with Paper II. Firstly, the sample size was somewhat 
modest and heterogeneous, which can affect the full spectrum of studied and 
unaffected variants in the population of concern. The number of informative 
haplotypes (DRB3*02‐DQA1*05:01‐DQB1*02:01) in our population was limited; 
consequently, the statistical power to distinguish the differential effect of DRB3*02‐
DQA1*05:01‐DQB1*02:01 and DRB3*01‐DQA1*05:01‐DQB1*02:01 was 
modest. Secondly, the study included study participants from an exclusive clinical 
site in Sweden, which can contain selection probability bias. The findings of Paper 
II, therefore, need to be replicated in more general populations before these risk 
estimations of individuals for CD can be established.  
Key genetic risk factors in CD are DQ2 (DQA1*05:01‐DQB1 *02:01), and DQ8 
(DQA1*03:01‐DQB1 *03:02) has physicochemical properties and binding of 
gliadin‐derived peptides deamidated by tissue transglutaminase 2 (tTG2). Both DQ2 
and DQ8 contain positively charged pockets with a preference for binding 
negatively charged particles. Specifically, in DQ2, the lysine position at β71 has a 
preference for binding with negatively charged residues at P4, P6, and P7 positions. 
The autoimmune disease relevance of the HLA-DQ8 polymorphic residue 57β was 
first identified for T1D (266). The DQ8 β57 polymorphism creates a basic 
environment with a preference for binding the negatively charged residue at P9 
(267). DR3 and DQ2 are in strong LD; therefore, now it is considered that it is the 
DQ2 molecule that predisposes to T1D as well, as DQ2 influences the selection and 
binding of the autoantigenic peptide. This is well elucidated for CD, in which 
negatively charged gliadin peptides as such or modified by tTG bind to DQ2/DQ8 
with high affinity. The lysine position at β71 in DQ2 binds to these residues at 
positions P4, P6, P7, and position β57 in DQ8 bind at P9 (268, 269). However, these 
mechanisms have not been fully resolved in T1D, as the triggering factor is not 
known in the last case, but it is anticipated that the “diabetogenic peptide” may be 
binding to DQ2 and DR3 accompanies it due to LD. Also, individuals who are 
homozygous for DQ2.5 or DQ8 have a five-fold higher risk of developing T1D than 
those who are heterozygous (270). The loss of aspartic acid at position 57 of 
diabetogenic HLA-DQβ chains supports Class II association with; this single amino 
acid change determines how TCRs recognize peptides in HLA-DQ8, and I-Ag7 
using a mechanism termed the P9 switch. Recently, studies provided a mechanistic 
molecular explanation that links the specific HLA class II polymorphism of T1D 
with the recognition of islet autoantigens and disease onset in mice (271). 
Besides, decreased costs of PCR, novel instrumentations, and approaches in 
bioinformatics, made NGS HLA typing affordable and accurate. Although Paper II 
showed differences between DRB3 *01‐DQA1 *05:01‐DQB1 *02:01 and DRB3 
*02‐DQA1 *05:01‐DQB1 *02:01 on the CD risk, there are noticeable potential 
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shortcomings with Paper II. Firstly, the sample size was somewhat modest and 
heterogeneous, which can affect the full spectrum of studied and unaffected variants 
in the population of concern. It can misrepresent the characterization of HLA 
diversity in the studied population. The number of informative haplotypes (DRB3 
*02‐DQA1 *05:01‐DQB1 *02:01) in the study population was limited; 
consequently, the statistical power to distinguish the differential effect of DRB3 
*02‐DQA1 *05:01‐DQB1*02:01 and DRB3 *01‐DQA1 *05:01‐DQB1 *02:01 was 
low. Secondly, the study included study participants from a particular clinical site 
in Sweden, which can contain selection probability bias. The sequencing of the HLA 
coding region solely will be inadequate for a complete understanding of the CD. 
Further analyses are required to determine the transcription of the key genes 
involved in the HLA functional pathway, along with physically interacting targets 
and/or further investigation of regulatory regions such as those containing 
transcription factor‐binding sites.  
Paper III: “High-resolution genotyping suggests that children with type 1 
diabetes and celiac disease share three HLA class II loci in DRB3, DRB4, and 
DRB5 genes” 
The main finding in Paper III demonstrated that three alleles, DRB4*01:03:01, 
DRB3*01:01:02, and DRB3*02:02:01, were found to be associated with T1D 
w/CD. Of these genes, DRB4*01:03:01 was associated with T1D only, 
DRB3*01:01:02 was associated with CD only, but inversely associated with T1D 
only. The DRB3*02:02:01 allele was associated with a low predisposition in all 
three groups. The novelty of the study lies in the fact that several alleles in DRB3, 
DRB4, and DRB5 genes in T1D w/CD children seem to have an extended HLA 
profile more similar to that in children with T1D only than that in children with CD 
only.  
Second, DRB4*01:03:01 containing haplotypes conferred an association with T1D 
w/CD as well as T1D in comparison to DRB3*01:01:02 containing haplotypes that 
were highly associated with CD. Around 50% of T1D and 70% of T1D w/CD 
haplotypes carry the former allele compared with 60% of CD who carry the latter 
allele. The analyses of the extended DRB1-DRB3-DRB4-DRB5 haplotypes likely 
suggests that the risk for developing both diseases likely resembles T1D risk. 
Third, differences between T1D w/CD and T1D children were found of whom T1D 
w/CD children were more likely to be homozygous for DR4-DQ8/DR4-DQ8 
compared to T1D children.   
In line with a previous study (80) the DR3-DQ2 haplotype occurred in over a third 
of T1D children, and as previously demonstrated, DR3-DQ2/DR4-DQ8 was the 
most frequent genotype (272). Moreover, HLA-DQ2.5 homozygosity was more 
common among CD children compared with T1D w/CD and T1D children, 
confirming the HLA dosage effect of DR3-DQ2 on the risk of CD (273). These 
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results are all in line with a previous Norwegian study (211), and a study conducted 
on Dutch patients (274) which showed that the T1D risk heterozygous genotype 
(DQ2.5/DQ8) provided a comparable frequency with T1D w/CD. In contrast to 
Bakker et al. (275) study that reported HLA-DQ2.5 homozygosity is expected in 
30% of the T1D w/CD group, indicating that a double dose of DQ2.5 confers the 
highest modifier for T1D patients to develop CD as shown previously (276). 
The strengths of the present study were the use of high-resolution NGS for extended 
HLA genotyping, which enabled examining the disease susceptibility between T1D 
w/CD and extended HLA-DRB3, DRB4, and DRB5 alleles. The RPE statistical 
analysis method used to estimate the association between HLA alleles (or 
haplotypes) and each of the outcomes (T1D only, CD only, T1D w/CD) accounts 
for the fact that a high frequency of a given allele “induces” a lower frequency of 
all other alleles, as their total must remain constant (260). A limitation of the study 
was the small sample size for the comparison of genotype effects both within and 
between the three disease groups. Secondly, the study included study participants 
from a single site comparing children at high-risk genotypes constituting a relatively 
homogeneous population with little HLA diversity. It cannot be ruled out that shared 
HLA loci may be different in other populations. 
Paper IV: “High-resolution genotyping of HLA class I loci in children with type 
1 diabetes and celiac disease” 
In Paper IV, extended polymorphism of HLA class I genes identified genetic 
diversities and similarities in children with T1D, CD, and in a subgroup of children 
having T1D w/CD of which eight alleles in the HLA-A region and six alleles in both 
HLA-B and HLA-C regions, respectively. Among those, only A*29:02:01 and 
C*05:01:01 showed a similar positive association between T1D w/CD, T1D and 
CD, indicating that shared genetic HLA class I loci for both diseases.  
Second, NGS identified A*68:01:02 as additional allele positively associated 
between T1D w/CD and T1D patients in addition to A*29:02:01; however, that was 
not shown in CD association frequency as it is only associated with A*29:02:01.  
Third, NGS results in T1D associated HLA-A and HLA-B alleles showed a 
distribution that was closer to T1D w/ CD than with CD. HLA-B alleles were mostly 
represented by two alleles, B*08:01:01 and B*15:01:01, similarly comparable 
between T1D and T1D w/ CD. Only one genotype, A*03:01:01-B*08:01:01-
C*03:04:01/A*24:02:01-B*15:01:01-C*07:01:01 was shared between T1D and 
T1D w/CD, albeit this genotype was only found in two children. All this points to 
the direction that HLA class I loci in T1D w/CD patients are more similar to that of 
T1D as compared to CD patients and suggest significant risk contribution of T1D 
risk alleles. 
The positive association of B*18 and A*24 with T1D is in line with previous reports 
(111, 277). In contrast to other studies, we found B*39:06 not to be associated with 
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T1D (105, 278). Since B*39 is relatively rare and found in 0.5–1.2% of Europeans, 
the different results between our and those previous studies might relate to regional 
differences in the study populations (279). Two previous studies have investigated 
the role of HLA class I and class II DRB1 and DQB1 on the risk of developing both 
T1D, CD or both diseases (T1D w/CD) and found that individuals with T1D w/CD 
are genetically more similar to T1D than to CD patients (210, 211). Two previous 
studies have investigated the role of HLA class I and class II DRB1 and DQB1 on 
the risk of developing both T1D, CD or both diseases (T1D w/CD) and found that 
individuals with T1D w/CD are genetically more similar to T1D than to CD patients 
(210, 211). In contrast to these previous studies that directly analyzed HLA class II 
in patients and control subjects, we utilized the NGTS for extended genotyping of 
HLA-A, B, and C without information on the descent. The sequencing of the coding 
region of exon 1-7 of HLA class I allowed the high-resolution detection of all 
associated genes differences in T1D and CD groups and subgroup T1D w/CD 
cohort. 
Our objective was to enhance our understanding of CD compared to T1D by asking 
if HLA class I genes contribute to T1D w/CD. In the future, this information might 
help in building precise genetic risk models to identify individuals with either T1D 
or CD who are at high risk of developing both. In comparison to our analysis, it is 
still the HLA class II loci that presents the most significant association with disease 
coexistence (280). However, our association study shows that the HLA class I 
alleles that are related to T1D w/CD are not the same as those related to the 
frequency distribution of either T1D or CD separately.  
A limitation of the present study is the inclusion of only a few patients with T1D 
w/CD. Despite this, it was possible through the RPE analysis to identify HLA class 
I alleles effect size that may have contributed to the development of both diseases. 
Another limitation is that it was not possible to include healthy children from the 
general population as a reference group for comparison. Although the underlying 
populations from which T1D and CD sets were collected from the same clinic, we 
addressed whether the allelic variation in the HLA region could be different between 
the two sample sets, which in turn could have resulted in predictable future disease 
risk.  
Overall, our conclusions indicate significant differences in the genetic structure in 
the HLA region, especially class I markers, between CD and T1D.  
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Conclusions 
Using high-resolution NGTS for extended HLA class I and class II genotyping in 
patients with T1D and CD, the conclusions from this thesis demonstrated that: 
I. HLA-DRB4*01:03:01 and DRB3*01:01:02 have a modifying effect to 
DRB1 on the risk of T1D (Paper I) 
II. HLA-DRB3*01:01:02 and DRB3*02:02:01 alleles in linkage with 
DQA1*05:01-DQB1*02:01 showed a differentiated effect on the risk of 
CD, which seem more predominant among patients of Scandinavian 
ethnicity (Paper II).  
III. HLA-DRB4*01:03:01, DRB3*01:01:02 and DRB3*02:02:01 were 
identified as three risk alleles shared between T1D and CD patients of which 
DRB4*01:03:01 conferred the strongest risk allele for developing T1D 
w/CD (Paper III).  
IV. The distribution of extended HLA-A and HLA-B alleles in T1D w/CD 
showed patterns closer to T1D but are different between children with T1D 
and CD. Only A*29:02:01 and C*05:01:01 showed a similar positive 
association between T1D w/CD, T1D and CD. (Paper IV) 
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Summary and Future perspectives  
The progress in characterizing HLA gene diversity, HLA associations with human 
diseases, and HLA–peptide–TCR interactions and their mechanistic immunologic 
implications have addressed the fundamental basis of this research area: to harness 
the improved understanding of HLA risk contribution for T1D and CD clinical 
benefit. With the ultimate aim of achieving precision or even personalized medicine, 
stratifying patients based on their HLA genotypes and administering antigen-
specific, patient-tailored disease prevention or immunotherapy presents a uniquely 
attainable target.  
Over the prior years, long-read, single-molecule DNA sequencing technologies 
have emerged as advancements in genomics. These platforms have demonstrated 
their strength to solve some of the most challenging human genome regions through 
generating reads tens to thousands of kilobases in length with precision approaching 
and high-resolution. Next-generation sequencing permits the full-length extended 
genotyping of diploid genomes, which revolutionized genomics by revealing the 
full spectrum of HLA genetic variation, resolving some of the missing heritability, 
and identifying novel mechanisms of autoimmune HLA-linked diseases. 
T1D is a mortifying disease that is a chronic condition requiring intensive treatment 
and, in the worst circumstances, may lead to an early death. The overall T1D burden 
must be decreased through early disease detection and early prevention by using 
immunogenetic characterization that draws a crucial factor in the pathway to T1D 
prevention. A prediction model by a combined risk score can enhance the prediction 
of T1D among susceptible patients. These types of interventions can significantly 
improve the cost and care of such patients.    
Despite the tremendous advances accomplished on the understanding of CD in the 
last decades, many issues remain unresolved, like why only a small fraction of HLA-
DQ2/DQ8 individuals develop CD or why this disease can appear at any time in 
life, from early childhood to late adulthood. Moreover, the percentage of diagnosed 
individuals who lack blood circulating antibodies against TG2 is reaching non-
negligible values. These fields of study may also be underlying clinical disease 
manifestations and have a lot to say in the development and progression of human 
diseases. 
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Precision medicine has found a sturdy hold in the diagnosis and treatment of 
diabetes. The ability to combine the diagnosis of diabetes into routine clinical care 
is one example where genetic diagnostics are inevitable and meet many of the 
properties of the prototypical test. Despite an excellent diagnostic standard, there 
are no known ways for preventing diabetes, although careful monitoring in pre-
symptomatic variant carriers may lead to early detection of diabetes and rapid 
treatment. Future precision diabetes medicine approaches are expected to introduce 
diagnostic genetic testing for predicting and determining diabetes subtypes to select 
the best interventional and therapeutic approaches.  
Development in transforming advances in biology and technology will be 
administered by the classification, precise estimation, and scalable deployment of 
diagnostic tools for diagnosis and therapy. Precision methods must be available to 
the full variety of human populations and societal settings, such that precision 
medicine does not widen health differences but delivers the most meaningful 
benefits for all individuals and society.  
Decades of research show that genetics represents an integral part of the etiology 
and pathogenesis of T1D and CD. An extended basis of knowledge has grown on 
the genetic factors that influence the development of both diseases. However, the 
genetics of T1D and CD are complex and polygenic. Besides HLA genetic factors 
directly associated with controlling immune response and beta-cell function, there 
is mounting proof that other missing hereditary may be involved.  
A meaningful application of genetics is to develop prediction in approaches that can 
be designed and achieved to counter disease in individuals at risk will be directed 
towards establishing: 
I. Extensive records of genotype-phenotype relationships in different 
populations and environments; 
II. Systematic assays of the variant- and gene-level function.  
III. Enhanced scalable strategies for using this basic genetic knowledge 
into completely developed molecular genetics models of T1D and 
CD pathogenesis; and 
IV. Application of genetic insights to stimulate new preventative and 
therapeutic alternatives. 
These advantages obtained by magnificent sequencing technology and collaborative 
research group outcomes will improve the understanding of the genetic basis of 
human disease. Data will drive translational innovations and widen access to large-
scale genetic resources.   
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